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ABSTRACT 
Introduction: Ataxia-telangiectasia (A-T) is an autosomal, recessive disorder that progressively 
affects multiple organs. A-T is caused by mutations in the Atm gene (ataxia-telangiectasia 
mutated gene), resulting in lack/inactivation of the ATM protein. These patients display a high 
incidence of insulin resistance or full-blown type 2 diabetes (T2D) and are therefore more prone 
to develop ischaemic heart disease. According to literature, ATM expression may be altered by 
obesity and therefore we investigated its expression and impact in the heart in the context of 
obesity-induced insulin resistance. 
Aim: To determine the importance of ATM in glucose uptake in cardiomyocytes prepared from 
control vs. obesity-induced insulin resistant animals. 
Objectives: (i) To determine ATM levels in rat models of obesity-induced insulin resistance and 
characterize a suitable model for the study. (ii) To manipulate the ATM protein in isolated 
cardiomyocytes from both control and insulin resistant animals using suitable activators or 
inhibitors of ATM followed by the measurement of 2-Deoxy-D-
3
[H] glucose (2DG) uptake levels, 
expression and activation of intermediates of the insulin signalling pathway (IRS1, PI3K, PTEN, 
PKB, AS160, GSK-3β, AMPK) and GLUT4 expression.  
Methods: Male Wistar rats were fed a high fat diet (HFD) for 16 weeks to induce obesity and 
insulin resistance and compared to chow-fed controls. Body weight, intra-peritoneal (IP) fat 
weight, fasting glucose and insulin levels were determined. Ventricular cardiomyocytes were 
prepared by collagenase perfusion digestion whereafter 2DG uptake was measured in response 
to treatment with specific activators/inhibitors of ATM. The specific ATM inhibitor, KU 60019, was 
used to manipulate the activity of the protein while the expression of proteins in the insulin 
signalling pathway was determined by Western blotting.  
Results: (i) No differences in body weight were observed. (ii) HFD animals presented with higher 
IP fat weight (33.7±2.4 vs. 19.1±1.5 g; p<0.001), basal glucose (5.4±0.16 vs. 4.71±0.05 mmol/L; 
p<0.001) and insulin (14.6±2.0 vs. 6.7±2.2 mlU/ml; p<0.05) levels vs. controls. (iii) KU 60019 
inhibited insulin-stimulated 2DG uptake in the control and HFD cardiomyocytes from 26.8±3.93 
and 28.38±1.27 to 13.1±2.4 (p<0.01) and 18.6±2.8 (p<0.05) pmol/mg prot/30min respectively. 
(iv) HFD downregulated T-ATM expression by 50% (1±0.1 vs. 0.5±0.1 ADU; p<0.001); T-PI3K 
by 30% (1±0.02 vs. 0.7±0.2 ADU; p<0.01); T-PKB by 40% (1±0.03 vs. 0.6±0.08 ADU; p<0.01); 
T-GSK-3β by 10% (1±0.02 vs. 0.9±0.05 ADU; p<0.01); T-AMPK by 30% (1±0.03 vs. 0.7±0.09 
ADU; p<0.05) and P-AS160 by 30% (1±0.08 vs. 0.7±0.2 ADU; p<0.001). (v) HFD increased the 
phosphorylation of IRS1 with 100% at Ser307 (1±0.3 vs. 2.2±0.1 ADU; p<0.05) vs. controls. (vi) 
Stellenbosch University  https://scholar.sun.ac.za
IV 
 
KU 60019 inhibited insulin-stimulated phosphorylation of ATM in the HFD animals (p<0.05). (vii) 
The inhibitory effect of KU 60019 on P-PI3K (p85) and P-PKB in both the control and HFD 
animals was significant (p<0.05 & p=0.001 respectively). (viii) In addition, by comparing results 
with younger animals, we observed age-related effects in insulin-sensitivity of cardiomyocytes.  
Conclusion: HFD was coupled to the development of insulin resistance, as these animals 
presented with higher IP fat weight, basal glucose and insulin levels and also downregulation of 
multiple metabolic signalling proteins and insulin sensitivity in the heart. Older control animals 
were also more resistant to the action of insulin than young animals. KU 60019 inhibited insulin-
stimulated 2DG uptake, placing ATM in the pathway whereby insulin stimulates glucose uptake 
in the heart. KU 60019 significantly attenuated baseline PI3K activity and insulin-stimulated 
activation of ATM and PKB but did not affect AMPK/GLUT4 levels. Thus downregulation of ATM 
expression in obesity may be central to the development of myocardial insulin resistance. 
Keywords: Obesity, insulin resistance, ATM, KU 60019, cardiovascular 
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OPSOMMING 
Inleiding: Ataxia-telangiectasia (A-T) is ‘n outosomale resessiewe siektetoestand wat verskeie 
organe progressief affekteer. Hierdie siektetoestand ontstaan weens mutasies in die Atm geen 
(ataxia-telangiectasia ge-muteerde geen), wat veroorsaak dat die ATM proteïen baie laag 
uitgedruk word of onaktief bly. A-T individue is meer vatbaar vir die ontwikkeling van insulien-
weerstandigheid asook diabetes tipe 2 (T2D) wat gevolglik hulle risiko vir iskemiese hartsiektes 
verhoog. Volgens vorige studies kan vetsug tot verlaagde ATM uitdrukking bydra. Weens 
laasgenoemde, het ons die uitdrukking/aktivering van ATM in die konteks van ‘n vetsug-
geïnduseerde insulien-weerstandige model in die hart ondersoek. 
Doelstelling: Om die belang van ATM in glukose opname te bepaal in kontrole en vetsug-
geïnduseerde insulin-weerstandige kardiomiosiete. 
Objektiewes: (i) Om ATM vlakke te bepaal in vetsug-geïnduseerde insulien-weerstandige rotte 
en sodoende ‘n geskikte model vir die studie te kies. (ii) Om ATM in geïsoleerde ventrikulêre 
kardiomiosiete van beide kontrole en vet diere met geskikte aktiveerders/inhibitore van ATM te 
manipuleer, waarna 2-Deoksi-D-
3
[H] glukose (2DG) opnames, die uitdrukking/aktivering van 
proteïene van die insulien-seintransduksie-pad (IRS1, PI3K, PTEN, PKB, AS160, GSK-3β, 
AMPK) en GLUT4 uitdrukking, bepaal sal word.   
Metodes: Manlike Wistar rotte is gebruik. Die helfte van hierdie rotte is ‘n hoë vet dieet (HFD) vir 
16 weke gevoer om vetsug/insulien-weerstandigheid te induseer, teenoor die kontrole diere wat 
slegs standaard rotkos ontvang het. Die liggaamsgewig, intra-peritoneale (IP) vet, vastende 
glukose- en insulien-vlakke is bepaal. Ventrikulêre kardiomiosiete van beide diergroepe is 
voorberei deur die harte met kollagenase te perfuseer waarna 2DG opname gemeet is t.o.v die 
behandeling met spesifieke aktiveerders/inhibitore van ATM. Die spesifieke ATM inhibitor, KU 
60019 is gebruik om ATM aktiwiteit te inhibeer. Die uitdrukking/aktivering van insulien-
seintransduksie proteïene is deur Westerse klad tegnieke bepaal. 
Resultate: (i) Daar was geen verskille in die liggaamsgewig tussen die diergroepe nie. (ii) HFD 
diere het hoër IP vet-massa (33.7±2.4 vs. 19.1±1.5 g; p<0.001), basale glukose vlakke (5.4±0.16 
vs. 4.71±0.05 mmol/L; p<0.001) en insulien-vlakke (14.6±2.0 vs. 6.7±2.2 mlU/ml; p<0.05) 
teenoor die kontrole diere gehad. (iii) KU 60019 het die insulien-gemedieerde 2DG opname 
respons in die kontrole en HFD diere onderskeidelik onderdruk vanaf 26.8±3.93 en 28.38±1.27 
tot 13.1±2.4 (p<0.01) en 18.6±2.8 (p<0.05) pmol/mg prot/30min. (iv) HFD het T-ATM uitdrukking 
met 50% verlaag (1±0.1 vs. 0.5±0.1 ADU; p<0.001); T-PI3K met 30% (1±0.02 vs. 0.7±0.2 ADU; 
p<0.01), T-PKB met 40% (1±0.03 vs. 0.6±0.08 ADU; p<0.01), T-GSK-3β met 10% (1±0.02 vs. 
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0.9±0.05 ADU; p<0.01), T-AMPK met 30% (1±0.03 vs. 0.7±0.09 ADU; p<0.05 en P-AS160 met 
30% (1±0.08 vs. 0.7±0.2; p<0.001) teenoor die kontroles. (v) HFD het IRS1 fosforilering(Ser307) 
met 100% verhoog (1±0.3 vs. 2.2±0.1 ADU; p<0.05) vs. die kontroles. (vi) KU 60019 het die 
insulien-gestimuleerde fosforilering van ATM in die HFD diere onderdruk (p<0.05). (vii) Die 
inhibitoriese effek van KU 60019 op P-PI3K en P-PKB in beide diergroepe was beduidend 
(p<0.05 & p=0.001 onderskeidelik). (viii) Deur resultate met jonger diere te vergelyk, is duidelike 
ouderdomsgeïnduseerde effekte op die insuliensensitiwiteit van kardiomiosiete waargeneem. 
Gevolgtrekking:  Die HFD het IP vet, basale glukose en insulien vlakke verhoog, asook verskeie 
metaboliese seintransduksie proteïne en insulien sensitiwiteit in die hart afgereguleer. KU 60019 
het insulien-gestimuleerde 2DG opname geïnhibeer, wat bewys dat ATM deel vorm van die pad 
waardeur insulien glukose-opname in die hart stimuleer. KU 60019 het die aktivering van basale 
PI3K afgereguleer sowel as die insulien-gestimuleerde aktivering van ATM en PKB, met geen 
effek op AMPK en GLUT4 vlakke nie. Dus mag die afregulering van ATM uitdrukking in 
vetsugtigheid sentraal staan in die ontwikkeling van miokardiale insulienweerstandigheid. 
Sleutelwoorde: Vetsug, insulien-weerstandigheid, ATM, KU 60019, kardiovaskulêr 
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CHAPTER 1: LITERATURE REVIEW  
 
1. Insulin resistant conditions  
Insulin resistance is a pathological condition in which muscle, liver and fat cells fail to properly 
respond to the hormone insulin. According to previous studies, obesity, especially the excess fat 
around the waist, is the primary cause of insulin resistance, imbalanced cholesterol, cardiovascular 
diseases (CVDs) and high blood pressure, due to several hormones and substances produced in 
the belly fat (National Institute of Diabetes and Digestive and Kidney Diseases - 
http://www.niddk.nih.gov). 
  
1.1. Definition and overview of obesity and its role in insulin resistance 
Obesity is defined as the accumulation of abnormal and excessive fat, mainly caused by the 
imbalance between energy intake and energy expenditure. The adipose tissue will 
consequently increase in the number of cells (hyperplasia) and the size of the cells 
(hypertrophy) to store the excess energy in the form of fat (Goedecke et al, 2006). 
According to the World Health Organization (WHO), a Body Mass Index (BMI) greater than 
or equal to 25 is considered as overweight whereas a BMI greater than or equal to 30 is 
considered as obese. The BMI, measured in kilograms (kg)/meter (m)2, is defined as a 
person’s weight in kg divided by the square of his height in m (www.who.int/en/). The BMI is 
useful as it can be used for both males and females; however it is not accurate when used 
on its own.  
According to 2015 updated WHO findings, the prevalence of obesity has more than doubled 
between 1980 and 2014. Data indicated that more than 1.9 billion adults, 18 years and older, 
were overweight in 2014. 600 million of these adults were classified as obese. In total, 13% 
of the world’s whole population was obese (15% women and 11% men), and this is still 
markedly increasing to such an extent as to be classified as a global epidemic.  
In countries undergoing epidemiological transition, including South Africa (Goedecke et al, 
2006), obesity mainly develops because of high carbohydrate consumption, as it is the main 
source of food due to low income levels in these areas. 
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In 2014, four out of 10 men (40%) and seven out of 10 women (70%) in South Africa were 
overweight or obese, thus causing South Africa to have the highest obesity rate in the sub-
Saharan Africa (Baleta & Mitchell, 2014). Of the 70% of women, 28% were overweight, 
whereas 42% were already suffering from obesity (Baleta & Mitchell, 2014).  
The association between insulin resistance, visceral fat and the metabolic syndrome is due 
to the enhanced lipolytic activity of visceral fat cells which causes increased free fatty acid 
(FFA) release into the portal (hepatic insulin resistance) and systemic (muscle insulin 
resistance) circulation (Defronzo, 2004). Insulin resistance results in increased blood glucose 
levels compensated for by insulin secretion from pancreatic β-cells. Increased demand on 
the pancreas coupled to high FFA levels is causative in β-cell failure and a subsequent 
inability to maintain euglycaemia, resulting in type 2 diabetes mellitus (T2D). Furthermore, 
the increased FFAs also lowers high density lipoprotein (HDL) levels and increases blood 
pressure and triglyceride levels respectively.  Together, all of these changes result in the 
development of cardiovascular diseases including atherosclerosis, ischemic heart disease 
and stroke (National Institute of Diabetes and Digestive and Kidney Diseases - 
http://www.niddk.nih.gov). 
 
2.  Physiological mechanisms of insulin action  
2.1. Overview of insulin action 
The insulin signal transduction pathway plays an important role in regulating blood glucose 
levels. This biochemical pathway can be affected by fed versus fasting states, certain 
hormones (Diabetes Education online, 2007-2016 - www.http://dtc.ucsf.edu) as well as 
stress levels (Livestrong, 2015 - www.livestrong.com). Carbohydrate consumption causes a 
subsequent rise in the blood glucose concentration. The β-cells, located in the pancreas, 
sense this increase and are consequently stimulated to secrete the hormone, insulin (Wilcox, 
2005).  
The tyrosine kinase insulin receptor (IR) (Figure 1.1), located on the cell surface of the 
plasma membrane of insulin sensitive peripheral cells, consists of two extracellular α-
subunits (~135 kilo Dalton (kDa)) and two transmembrane β-subunits (~95 kDa) (Yanagita et 
al, 2013). Once the secreted insulin molecule binds to the α-subunit, it results in the 
autophosphorylation of the β-subunit tyrosine residues. Consequently proteins containing 
phosphotyrosine-binding (PTB) as well as Src homology 2 (SH2) domains will be recruited 
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as these proteins have the ability to identify the phosphorylated tyrosine receptor residues 
(Yanagita et al, 2013). 
 
 
 
 
 
 
 
Figure 1.1: The insulin receptor 
According to previous research, the IR substrates (IRS)-1/2 as well as SHC are the two 
scaffold proteins which are most likely to be recruited to the IR. Once these scaffold proteins 
are recruited, they link the activated IR to two parallel downstream signal transduction 
pathways including the: phosphoinositide 3-kinase (PI3K)/ phosphoinositide-dependent 
kinase 1 (PDK-1)/ Protein kinase B (PKB) pathway as well as the Ras/ Extracellular signal-
regulated kinase (ERK) pathway (van der Heide et al, 2006; Wada et al, 2005). 
 
To date, there are four IRS molecules identified: IRS1, IRS2, IRS3 and IRS4. All of these 
molecules can act as a docking protein between the IR and several intracellular signalling 
molecules containing a SH2 domain. These molecules are especially important in regulating 
not only insulin signalling, but also several basic cellular functions such as metabolism, 
growth and survival (Sesti et al, 2001). In the next section, the link between the four different 
IRS molecules and insulin signalling respectively will be discussed. 
(i) IRS1 
The IRS1 molecule contains 21 assumed tyrosine phosphorylation sites. Several of these 
sites are believed to be located in amino acid sequence motifs, which give IRS1 the ability to 
bind to SH2 domain proteins, including the p85 regulatory subunit of PI3K, Growth factor 
receptor-bound protein 2 (Grb2), Adapter molecule crk (Crk), C-Src kinase (Csk), Proto-
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oncogene tyrosine-protein kinase Fyn (Fyn), protein tyrosine phosphatase (PTPase) SHP-2, 
non-catalytic region of tyrosine kinase adaptor protein 1 (Nck) and phospholipase Cγ (PLC) 
(White, 1997). Furthermore, IRS1 also contains 30 serine/threonine phosphorylation sites in 
motifs. These motifs are recognized by several kinases including protein kinase C (PKC), 
PKB, casein kinase II (CK2) and mitogen-activated protein (MAP) kinases (White, 1997; Sun 
et al, 1991). 
In response to insulin binding, IRS1 is believed to be the main docking protein responsible 
for the activation of PI3K (Rondinone et al, 1997).  
Several studies performed on different tissues in human and mouse respectively indicated 
that IRS1 plays an important role in mediating both mitogenic as well as metabolic effects of 
insulin in the peripheral tissues (muscle, adipose) (Sesti et al, 2001). It was also discovered 
that IRS1 plays a key role in regulating insulin secretion in pancreatic β-cells in mice. Once 
IRS1 was supressed, the islets were incapable to secrete sufficient amounts of insulin in 
response to increased glucose levels (Kulkarni et al, 1999).  
 
(ii)  IRS2 
 
The IRS2 protein is functionally and structurally similar to the IRS1 protein, however the 
IRS2 protein is believed to be 100 residues longer than IRS1 (Sun et al, 1995). 
As IRS1, the IRS2 protein also contains tyrosine phosphorylation sites (22 potential sites). 
When the amino acid sequences of IRS1 and IRS2 were compared, 43% of the sequences 
were similar, whereas the Pleckstrin homology domain (PH) (65%) and PTB (75%) domains 
exhibited a higher degree of similarity respectively (Sesti et al, 2001). 
Interestingly, IRS2 contains a unique middle region in its structure, which gives it the ability 
to bind specifically with the kinase regulatory loop binding (KRLB) domain of the IR β- 
subunit (Sawka-Verhelle et al, 1996). This unique middle amino acid region is absent in 
IRS1, which makes IRS2 signalling specific. 
The distribution of IRS1 and IRS2 in the fat cell was found to differ causing each one of 
these proteins to have different activation and deactivation kinetics. The IRS1 protein was 
twofold more concentrated in the intracellular membrane compartment when compared to 
the cytosol of 3T3-L adipocytes, whereas IRS2 was twofold more concentrated in the cytosol 
than in the intracellular membrane compartment (Inoue et al, 1998). 
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According to previous studies, the IRS2 protein, in comparison to IRS1, becomes 
dephosphorylated very speedily and also activates PI3K more rapidly. These differences in 
the activation kinetics play an important role in especially the insulin signalling pathway 
(Ogihara et al, 1997; Inoue et al, 1998). 
Furthermore, the differences in distribution also affect the interaction of these proteins 
respectively with downstream effectors containing the SH2 domain (Shuppin et al, 1998; Sun 
et al, 1997; Giovannone et al, 2000). Both IRS1 and IRS2 binds to: PI3K, Crk, phospholipase 
Cγ, Fyn and Grb2, however only IRS1 binds to SHP-2 (White, 1997; Sun et al, 1997). 
 
(iii)   IRS3 
 
IRS3, originally associated with only the adipose tissue is interestingly also expressed in the 
heart, kidney, liver, ovaries, fibroblasts, lung, betacellulin-1 (bTC-1) and betacellulin-7 (bTC-
7) insulinoma cells (Giovannone et al, 2000; Sciacchitano & Taylor, 1997). 
IRS3 is primarily located in the plasma membrane where it senses insulin (Anai et al, 1998), 
however in humans no IRS3 proteins are expressed (Sesti et al, 2001). 
The IRS3 protein (in rat adipocytes), is 700-800 amino acid residues shorter than IRS1 and 
IRS2, however its PH domain, PTB domain and carboxyl (COOH)-terminal domain is similar 
to IRS1 (Sesti et al, 2001).  
When the PH domain of IRS3 in rats was compared to IRS1 and IRS2, a similarity in the 
sequence identity of 50% (IRS1) and 45% (IRS2) respectively was observed. Furthermore, 
the PTB domain of IRS3 in rats displayed a similarity sequence identity of 48% (IRS1) and 
53% (IRS2) (Lavan et al, 1997). The COOH-terminal domain of IRS3 contains less (13) 
tyrosine phosphorylation sites when compared to IRS1 (30) and IRS2 (22).  
Furthermore, as IRS1 and IRS2, IRS3 also has the ability to potently bind to PI3K, SHC-
transforming protein 1 (Shc), SHP-2 and Nck, but slightly less potent to PLC and Grb2 (Xu et 
al, 1999). When IRS3 was overexpressed in rat adipocytes, a robust increase in Glucose 
transporter 4 (GLUT4) vesicle translocation was observed, with or without insulin stimulation 
(Zhou et al, 1999). 
Interestingly, when rat adipocytes were exposed to insulin, the p85 regulatory subunit of 
PI3K associated more rapidly with IRS3 than IRS1 and IRS2 (Smith-Hall et al, 1997). 
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(iv)   IRS4 
 
IRS4, the last IRS protein, was originally only observed at very low levels in human 
embryonic kidney 293 cells (Giovannone et al, 2000; Fantin et al, 1999; Uchida et al, 2000). 
Interestingly IRS4 was recently also observed in several human tissues and cell lines 
including the ovary, pituitary thyroid, fibroblasts, IM-9 lymphoblastoid cells, prostate, A-431 
epidermoid carcinoma cells, U-2 osteogenic sarcoma (OS), Hep-2 larynx carcinoma cells, 
and several murine tissues including the brain, heart, skeletal muscle, bTC-1 and bTC-7 
insulinoma cell lines, kidney, hypothalamus, liver, but not in the lung or spleen (Giovannone 
et al, 2000; Fantin et al, 1999; Uchida et al, 2000). At subcellular level, IRS4 is believed to be 
the most abundant in the plasma membrane (Tsuruzoe et al, 2001). 
As the other IRS members, IRS4 also consists of a PH domain, a PTB domain and a COOH-
terminal domain (Lavan et al, 1997). When the sequence identity of IRS4 was compared to 
IRS1 and IRS2, a similarity of only 27% and 29% respectively was observed (Sesti et al, 
2001). The IRS4 protein however shares a high degree of ancestry (homology) with the 
IRS1, IRS2 and IRS3 protein domains.  
Similar to the other IRS proteins, IRS4 also contains potential tyrosine phosphorylation sites 
(12), where 7 of these sites are associated with the YXXM (Tyrosine- XX- Methionine where 
X is any amino acid) motif and therefore has the ability to bind to the SH2 domain of the p85 
regulatory subunit of PI3K. Furthermore, IRS4 also consists of two more potential tyrosine 
phosphorylation sites that lie in motifs that are known to bind to the SH2 domain of Grb2 and 
the NH2-terminal domain of either PLC or SHP-2 (Sesti et al, 2001).   
Up to date, a definite role for IRS4 has not yet been established, but several possible 
functions include: regulation of pathways involved in cell differentiation, increasing GLUT4 
vesicle translocation in the adipose tissue (Zhou et al, 1999) and increasing cell proliferation 
by stimulating the capability of insulin-like growth factor-1 (IGF-I) and insulin in fibroblasts 
and hematopoietic cells (Fantin et al, 1999; Qu et al, 1999). In previous studies, the 
overexpression of IRS4 resulted in the downregulation of IRS1 and IRS2 phosphorylation 
indicating that IRS4 probably acts as a negative regulator of IGF-1 signalling (Uchida et al, 
2000). More recent studies indicated that IRS3 and IRS4 might act as IRS1 and IRS2 
suppressors at numerous steps (Tsuruzoe et al, 2001).  
When IRS3 and IRS4 were simultaneously overexpressed, a reduction in IRS2 messenger 
ribonucleic acid (mRNA) and in the association of IRS1 and IRS2 with PI3K was observed 
Stellenbosch University  https://scholar.sun.ac.za
7 
 
(Tsuruzoe et al, 2001). The overexpression of only IRS3 resulted in downregulated IGF-I-
stimulated tyrosine phosphorylation of IRS1 (Tsuruzoe et al, 2001).  
From the above it is evident that the IRS proteins affect one another, and work together in 
combination to control several mechanisms in response to insulin.  
In the next section, the two best-studied insulin responsive pathways, including the PI3K-
dependent and the PI3K-independent pathway respectively, are described.  
 
2.2. Insulin stimulation and signalling in the peripheral tissue 
 
2.2.1. PI3K-dependent pathway 
 
PI3K is a heterodimer tyrosine regulated kinase composed of a 110 kDa catalytic subunit 
(p110) and an 85 kDa regulatory/adapter subunit (p85).  The p85 regulatory subunit 
consists of two SH2 domains (separated by an inter-SH2 domain), a SH3 domain and a 
proline rich breakpoint cluster region (BcR) homology domain (Dhand et al, 1994; Holt et 
al, 1994; Klippel et al, 1994). 
The p110 catalytic subunit has a catalytic domain, a p85-interacting region (binds at the 
SH2 domains of p85), a homologous phosphatidylinositol-4-OH kinase (PI4K) region and 
a Ras-binding domain (Zvelebil et al, 1996; Dhand et al, 1994). 
The association of the SH2 domains of the p85 subunit with the pTyr of IRS1 allows the 
association of the p110 subunit with the p85 subunit to form the enzyme PI3K. 
The activation of PI3K is crucial for insulin-stimulated glucose uptake (Figure 1.2). PI3K 
is a lipid kinase containing phospholipids that forms part of the plasma membrane. This 
enzyme transfers phosphate molecules to the 3 position hydroxyl group of the 
phosphoinositol ring lipids, consequently resulting in phosphoinositide 3,4-bisphosphate 
(PtIns(3,4)P2 and phosphoinositide (3,4,5) trisphosphate (PtIns(3,4,5)P3 formation.  
These 3-phosphorylated lipids create docking sites in the membrane that acts as rafts 
where proteins containing PH domains, such as PDK1, PKB and mammalian target of 
rapamycin (mTOR) c2 can associate/activate (Scheid & Woodgett, 2003). PKB is 
phosphorylated on its Thr308 residue by PDK1 and on its Ser473 residue by mTORc2 
amongst others. Ser473 phosphorylation is usually seen as the final event to activate 
PKB. 
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Once PKB is active, the PH domain results in the activation of two different pathways: (i) 
Rab pathway and (ii) glycogen synthase kinase 3β (GSK-3β) pathway. In the first 
pathway (i) PKB phosphorylates the domain family member 4 (TBC4), also known as Akt 
substrate of 160 kDa (AS160), which results in the inhibition of the AS160 associated 
GTPase-activating domain. Thus AS160 becomes less active and relieves its inhibitory 
effect on Rab. The Rab protein is converted from its GDP bound form to a GTP bound 
state. In addition, activated Rab stimulates GLUT4 vesicle translocation to the membrane 
for glucose uptake (Bevan, 2009; Cell Signaling (2013) - www.cellsignal.com). 
Furthermore, PKB can (ii) directly phosphorylate GSK-3β, resulting in inactive GSK-3β 
which no longer inhibits glycogen synthase (GS). Consequently, glycogen synthesis is 
induced to convert glucose to glycogen molecules (Bevan, 2009). 
The catalytic domain of PKB also results in the activation of two different pathways 
including: (i) Forkhead box protein O1 (FOXO) pathway and (ii) mTOR pathway (Cell 
Signalling (2013) - www.cellsignal.com).  
(i) FOXO1 is localized in the nucleus where it plays an important role in glucose 6-
phosphatase (G6Pase) transcription. When PKB in the liver is activated in response to 
insulin stimulation, it translocates to the nucleus and phosphorylates FOXO1 at Ser256, 
Ser319 and Thr24 thereby initiating this protein to move out of the nucleus for 
degradation purposes. In response to this degradation, G6Pase transcription will be 
downregulated resulting in reduced glucose production in the liver (Nakae et al, 2001). 
(ii) PKB furthermore phosphorylates tuberous sclerosis 1 (TSC1) causing the Ras 
homolog enriched in brain (RHEB) protein to change from its inactive to active form.  
Consequently, mTOR will be activated to induce protein synthesis via the eukaryotic 
translation initiation factor 4E-binding protein 1 (4EBP1) and p70s6k (Bevan, 2009). 
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Figure 1.2: The PI3K-dependent pathway 
2.2.2. PI3K-independent pathway 
PI3K-independent signalling (Figure 1.3) includes the activation of two different pathways 
in response to insulin (Bevan, 2009).  
In the first pathway (i) GLUT4 vesicle translocation is induced without the activation of 
PI3K. This pathway basically entails the activation of the IR in response to insulin 
secreted from the pancreas. Once the tyrosine residues of the IR are phosphorylated, the 
Cbl-CAP complex is phosphorylated and in response translocated to lipid rafts in the 
plasma membrane (Bevan, 2009). Following this, Cbl activates the Crk protein which is 
associated with Guanine nucleotide exchange factor (C3G).  
Active C3G phosphorylates the GDP bound protein, TC10. Consequently GDP will be 
dissociated, and TC10 will bind to GTP. The active TC10 protein promotes GLUT4 
vesicle translocation to the plasma membrane; however the mechanism of action is still 
unclear (Chiang et al, 2001).  
   The second pathway will only be briefly described as it is beyond the scope of this thesis. 
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In this pathway (ii), the SH2 domain of IRS1 binds to Grb2. The phosphorylated Grb2 
protein consequently has the ability to bind to the Son of sevenless homolog 1 (SOS) 
protein. Once the SOS protein is activated, the GDP bound Ras is converted to a GTP 
bound Ras, resulting in the initiation of a phosphorylation cascade including Raf, 
Mitogen-activated protein kinase kinase (MEK) and ERK. Stimulated ERK results in gene 
transcription and regulation of various signalling pathways (Bevan, 2009). 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The PI3K-independent pathway 
It is however important to note that the effects of insulin vary depending on the tissue 
involved. The different tissues described in section 2.3 include: adipose, skeletal muscle, 
heart and the liver.  
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2.3. Tissue specific insulin signalling in the context of glucose uptake in: (i) adipose 
tissue, (ii) skeletal muscle, (iii) heart and (iv) the liver: 
2.3.1. Insulin signalling in the adipose tissue 
Once insulin is secreted from the β-cells in the pancreas, it activates the relevant 
signalling pathways in adipocytes via the IR as described in Chapter 1, Section 2.2.1 and 
increase GLUT4 vesicle translocation for glucose uptake. Consequently the sterol 
regulatory element binding protein-1c (SREBP-1c) is also activated and lipogenesis is 
induced to store energy in the form of fat (Rask-Madsen & Kahn, 2012).  
2.3.2. Insulin signalling in the skeletal muscle  
Secreted insulin binds to the IR on the cell surface of the myocyte. The signal is 
transmitted intracellularly to IRS1 as described in Chapter 1, Section 2.2. Once 
phosphorylated, PI3K and PKB respectively undergo phosphorylation. PKB induces the 
translocation of GLUT4 vesicles to the plasma membrane, consequently increasing 
glucose uptake in the cell (Rask-Madsen & Kahn, 2012). PKB also initiates glycogen 
synthesis via the activation of GS (Pessin & Saltiel, 2000) and protein synthesis via the 
activation of mTOR/ 4EBP1/ p70s6k (Rask-Madsen & Kahn, 2012). 
2.3.3. Insulin signalling in the heart 
As described in Chapter 1, Section 2.2, insulin once again enters the heart tissue via the 
IR. Consequently, the PI3K-dependent pathway is activated resulting in GLUT4 vesicle 
translocation for glucose uptake. Furthermore, insulin also activates cardiac 6-
phosphofructo-2-kinase (PFK-2) via the PI3K/PDK-dependent pathway (Mouton et al, 
2007; Lefebvre et al, 1996; Bertrand et al, 1999; Pozuelo et al, 2003; Deprez et al, 2000). 
This PFK-2 enzyme specifically synthesizes fructose 2,6-bisphosphate (Fru-2,6-P2) 
(Rider & Hue, 1984), which, in addition, activates the main glycolytic regulator enzyme, 
phosphofructo-1-kinase  (PFK-1). As an end result, glucose will be degraded into 
pyruvate. The direct activation of PFK-2 is however not yet identified (Mouton et al, 2007; 
Bertrand et al, 1999). 
As glucose enters the heart tissue, insulin simultaneously also stimulates the 
translocation of fatty acid translocase (FAT/CD36) transporters to the plasma membrane 
via the PI3K pathway (Luiken et al, 2002). Subsequently long-chain fatty acid (LCFA) 
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uptake (Glatz et al, 2006; Coort et al, 2007) is initiated resulting in intracellular lipid 
storage (Dyck et al, 2001). 
2.3.4.  Insulin signalling in the liver 
Once insulin enters the hepatocyte via the IR, it activates three different pathways. In the 
first pathway (i), PKB and FOXO are respectively phosphorylated and the glucose output 
by the liver is consequently decreased via the downregulation of G6Pase transcription. In 
the second pathway (ii), myosin heavy chain (MHC) and proprotein convertase 
subtilisin/kexin type 9 (PSCK9) are phosphorylated, resulting in increased protein 
synthesis. In the third pathway (iii), SREBP-1c results in the initiation of lipogenesis 
(Rask-Madsen & Kahn, 2012). 
2.4.  Termination of the insulin pathway 
Insulin signalling is attenuated via the phosphatase SH2 domain-containing inositol 5'-
phosphatase (SHIP) and a tensin homolog phosphatase (PTEN). Both these phosphatases 
dephosphorylate and consequently degrade PIP3 to PIP2 (Lazar & Saltiel, 2006). The 
PTPase SHP2 can also directly dephosphorylate IRS1 to prevent the activation of PI3K. 
Lastly, insulin signalling is further attenuated when insulin is degraded by the insulin 
degrading enzyme (IDE) and when the insulin-IR complex is internalized into endosomes 
(Bevan, 2009). During endocytosis, insulin molecules will be degraded whereas the IR’s are 
recycled to the plasma membrane.  
  
2.5.  Activators and inhibitors of the PI3K-dependent pathway (used in the current 
study) 
 
2.5.1. Insulin  
 
The activation of the PI3K-dependent pathway in response to insulin is described in 
Chapter 1, Section 2.2.1. 
2.5.2. Wortmannin (WM) 
WM is a specific, covalent PI3K inhibitor. The structure consists of a highly reactive 20 
carbon ring which is responsible for the inhibition of the PI3K.  Due to WM’s low half 
maximal inhibitory concentration (IC50) value (5nM) in vitro, it is considered as the most 
potent PI3K inhibitor. When used at low concentrations, WM is believed to have equal 
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inhibitory potency for PI3Ks class I, II and III. When used at a higher concentration, WM 
also has the ability to inhibit other PI3K related enzymes including: the Ataxia 
telangiectasia Mutated (ATM)- related deoxyribonucleic acid (DNA)-dependent protein 
kinase (DNA-PKc), mTOR, Mitogen-activated protein kinase (MAPK), myosin light chain 
kinase (MLCK) as well as some of the PI4KAs (Ferby et al, 1996; Vanhaesebroeck et al, 
2001; Wymann et al, 1996). According to Sarkaria et al (1998), WM can also inhibit ATM 
with an IC50 of 150 nM. 
 
3.  The link between obesity and insulin resistance  
 
More individuals are globally diagnosed with T2D as a consequence of obesity and insulin 
resistance. Insulin sensitivity can however be influenced by the fat distribution in the body. 
According to research, individuals with high levels of visceral fat (upper body fat) are more 
susceptible to develop insulin resistance than individuals with lower body fat (Defronzo, 2004). 
This association between increased visceral fat and insulin resistance development can be 
attributed to the enhanced lipolytic activity observed in visceral fat cells, which initiates the 
release of FFA into circulation (systemic and portal) (Defronzo, 2004). 
  
3.1. Inflammatory response in adipocytes 
  
Obesity is associated with adipocytes which increase in size (hypertrophy) and number 
(hyperplasia) to store excess nutrients in the form of fat. 
According to Virtue (2010), hypertrophied adipocytes induce the activation of several 
chemokines. The chemokines recruit macrophages which, in response, secrete pro-
inflammatory cytokines e.g. tumor necrosis factor- alpha (TNF-α) and Interleukin-6 (IL6). 
Once inflammation is induced, it results in the development of insulin resistance in the 
mature adipocytes (Virtue, 2010). Insulin resistant adipocytes release more FFAs which 
initiates further recruitment and activation of macrophages. Activated macrophages inhibit 
pre-adipocyte formation, consequently causing the mature adipocytes to become more 
insulin resistant, inducing more FFA release and additional macrophage activation (Virtue, 
2010). 
 
3.2. FFA release 
 
Obesity is in addition, associated with enhanced lipolytic activity in the visceral fat cells which 
causes a subsequent rise in the amount of FFA released into the portal and systemic 
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circulation (Defronzo, 2004). This acute rise in the amount of circulating FFA in pre-diabetic 
individuals stimulates insulin secretion. However in these individuals, the amount of insulin 
secreted is not sufficient to compensate for the FFA-induced insulin resistance (Boden, 
2008). Consequently, hepatic- and muscle insulin resistance can develop in turn (Defronzo, 
2004). 
 
3.3. Oxidative stress 
Oxidative stress (OS) refers to the imbalance between the production of reactive oxygen 
species (ROS) and antioxidant defences to detoxify/neutralize these species (Rains & Jain, 
2011). According to Rain & Jain (2011) oxidative stress is a contributor to the (i) onset of 
diabetes, (ii) progression of diabetes and (iii) complications associated with diabetes, including 
insulin resistance and β-cell dysfunction.   
As mentioned in Chapter 1, Section 3.1, obesity is associated with increased proinflammatory 
cytokine production, including TNF-α and IL-6 (Fernandez et al, 2011). Both these cytokines 
stimulate ROS and reactive nitrogen species (RNS) production via monocytes and 
macrophages. Furthermore, TNF-α also inhibits the activity of polymerase chain reaction 
(PCR), consequently increasing the interaction of electrons with oxygen, resulting in 
superoxide anions formation (Fonseca-Alaniz et al, 2007). In addition, the adipose tissue also 
secretes angiotensin II, which results in the stimulation of Nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase activity. NADPH oxidase is a major contributor for ROS 
production in adipocytes (Morrow, 2003). 
 
4.  Link between insulin resistance and T2D 
T2D is a metabolic disorder that is associated with high circulating blood glucose levels 
(hyperglycemia), resulting in insulin resistance in the liver and muscle tissue respectively. Insulin 
resistance in the liver is characterized by faulty suppression of hepatic glucose production (HGP) 
and increased lipoprotein uptake, whereas insulin resistance in the muscle is associated with 
impaired glucose uptake via GLUT4 and declining glycogen synthesis (Defronzo, 2004). 
When insulin resistant, insulin secretion from the β-cells in the pancreas increases to maintain 
normal circulating glucose levels. However as insulin resistance in the liver and the muscle 
worsens, the release of insulin becomes disrupted. This disruption results in declining early 
phase insulin secretion followed by excessive late phase insulin secretion. This observation of 
Stellenbosch University  https://scholar.sun.ac.za
15 
 
irregular insulin secretion is considered as the onset of impaired glucose tolerance (IGT) 
(Defronzo, 2004).  
IGT results in T2D when the pancreas is not capable to secrete the optimal amount of insulin 
needed. Consequently, insulin secretion sharply declines as the glucose concentration continues 
to rise (Defronzo, 2004). 
 
5. Insulin resistance, T2D and CVD 
The disturbance of insulin signalling plays a central role in the development of the metabolic 
syndrome.  Due to these disruptions, one is more prone to develop CVDs and vascular 
complications as a result of the inflammatory, hyperglycemic, hypertensive and dislipidemic 
environment created by T2D (Rask-Madsen & Kahn, 2012). 
In the next section, the link between cardiovascular complications and insulin resistance in the 
(5.1) endothelial tissue, (5.2) macrophages and (5.3) cardiac tissue is respectively described: 
 
5.1. Insulin resistance in the endothelial tissue  
Previous studies (Kubota et al, 2011; Kim et al, 2007) observed that in diet-induced obese 
rats, insulin was not able to activate PKB and nitric oxide (NO) synthase in aortic tissue 
indicating insulin resistance. Insulin resistance is associated with increased leukocyte 
adhesion to the endothelium, increased expression of the vascular cell adhesion molecule-1 
(VCAM-1) and impaired NO-mediated vasorelaxation (Rask-Madsen et al, 2010). 
The downregulation of VCAM-1 in response to insulin stimulation is not blocked by NO-
synthase inhibitors, confirming that insulin signalling independent of NO is responsible for 
VCAM-1 expression (Rask-Madsen & Kahn, 2012). Furthermore, insulin resistance in the 
endothelial tissue results in increased vascular wall inflammation and atherosclerosis.   
Insulin resistance in the endothelial cells develop through: (i) the activation of toll-like 
receptor 4 (TLR4) in response to increased FFA levels (Kim et al, 2007), (ii) the 
downregulation of the IRS proteins (Kubota et al, 2011) and also (iii) the elevated TNF-α and 
other pro-inflammatory cytokines released from the adipose tissue (Rask-Madsen et al, 
2003). 
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Mechanism: Once insulin binds to its receptors on the endothelial cells, it activates PKB. 
Following this, PKB translocates to the nucleus and consequently phosphorylates FOXO1. 
(Nakae et al, 2001; Rask-Madsen et al, 2012). 
When FOXO1 is phosphorylated, it downregulates VCAM-1 expression (Rask-Madsen & 
Kahn, 2012) and decrease leukocyte adhesion to the endothelium. Insulin resistance is 
however coupled to upregulated VCAM-1 expression and leukocyte adhesion to the 
endothelium resulting in cardiovascular damage (Rask-Madsen et al, 2003). Thus, the 
phosphorylation of FOXO1 in endothelial cells can prevent atherosclerosis development in 
individuals suffering from the metabolic syndrome (Rask-Madsen & Kahn, 2012).  
5.2. Insulin resistance in macrophages 
Insulin resistance in macrophages causes a subsequent rise in cluster of differentiation 36 
(CD36) expression which results in increased LDL uptake (Han et al, 2006) and pro-
inflammatory cytokine inhibition (Baumgartl et al, 2006).  CD36 is a glycoprotein which 
endocytose oxidized low density lipoproteins (OxLDL) (Collot-Teixeira et al, 2007). 
Consequently, these insulin resistant macrophages will undergo increased apoptosis (Han et 
al, 2006) causing the formation of a necrotic core in the atherosclerotic plaques. Once the 
plaques rupture, the necrotic core is exposed to circulating blood and raises the susceptibility 
to develop thrombosis, transitory cerebral ischemia, unstable angina pectoris, myocardial 
infarction and stroke (Moore & Tabas, 2011).  
 
5.3. Insulin resistance in the cardiac tissue 
 
Obesity is associated with changes in the myocardial metabolism such as: higher fatty acid 
oxidation and lower glucose oxidation rates (Mazumder et al, 2004). This switch is due to the 
increased FFA production and release into circulation during obesity. 
Furthermore obese animals tend to have higher expression of the β isoform of the MHC. The 
expression of this isoform is especially upregulated during remodelling in cardiac failure 
(Rask-Madsen & Kahn, 2012), consequently resulting in downregulated contractile properties 
and increased disease progression (Kiriazis & Kranias, 2000; Fatkin et al, 2000). 
Insulin resistance in the cardiac muscle is associated with reduced cardiomyocyte volume, 
decreased GLUT4 expression, decreased GLUT1 expression (Rask-Madsen & Kahn, 2012) 
as well as the excessive β-oxidation of FFA in the mitochondria (Koves et al, 2008). These 
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changes, especially in metabolic substrate inflexibility and increased oxidant production in 
the mitochondria, can cause the development of heart failure (Rask-Madsen & Kahn, 2012).    
 The insulin-like growth factor-1 receptor (IGF1R) compensates to a small extent for insulin 
signalling in insulin resistant cardiomyocytes. However, once the IGF1R becomes 
unresponsive due to the loss of insulin sensitivity, fatty acid β-oxidation in the mitochondria is 
increased and the expression of the contractile proteins is downregulated (Rask-Madsen & 
Kahn, 2012). As a result, heart failure and cardiomyopathy will develop (Laustsen et al, 
2007). 
 
5.4. Coronary heart disease (CHD) 
CHD is generally caused by atherosclerosis which refers to plaque build-up in the arterial 
walls. According to the American Heart Association, plaque consists of fatty substances, 
cholesterol, calcium, cellular waste products, and the clotting material, fibrin. Plaque 
formation results in: arterial wall narrowing; restriction of oxygenated blood supply to the 
heart consequently causing angina pectoris (chest pain); heart attack (myocardial infarction) 
and shortness of breath amongst others (Singh, 2014).  
Over time, plaque in the arteries can harden causing the coronary arteries to narrow and 
reduce oxygen-rich blood flow to the heart to a further extent. The plaque can also rupture 
resulting in the formation of a blood clot, which can partially or completely block the blood 
flow thorough the coronary artery (Mayo Clinic Health - www.mayoclinic.org).  
The most common coronary heart disease risk factors include: obesity, T2D, hypertension, 
high circulating blood lipids, smoking, a lack of exercise and stress (Singh, 2014). According 
to Kivimäki et al (2012), smoking contributes to 36% of CHD development followed by 
obesity which is associated with 20% of the cases. 
5.4.1. Heart failure 
Heart failure, also known as chronic heart failure (CHF), is a condition where the heart is 
unable to pump a sufficient amount of blood to meet the body’s needs (Dorland's Medical 
Dictionary; Medical Dictionary, 2011; Mayo Clinic, 2009). In individuals suffering from 
heart failure, the heart is either unable to be filled with enough blood, or unable to provide 
enough blood to the rest of the body (National Clinical Guideline Centre (2010) – 
www.ncgc.ac.uk).  
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Heart failure is associated with the development of weaker heart pumping as the 
condition progresses over time. Heart failure can affect both sides of the heart. Right-side 
heart failure is associated with the inability of the heart to pump blood to the lungs for 
oxygen exchange whereas left-side heart failure refers to the inability of the heart to 
pump oxygenated blood to the whole body. Individuals suffering from heart failure 
develop symptoms such as leg, feet and ankle swelling; shortness of breath; and 
excessive fatigue (McDonagh, 2011). 
5.4.2. Diabetic cardiomyopathy 
Diabetic cardiomyopathy, a term originally introduced by Rubler and collogues in 1972, is 
a condition where T2D affects the cardiac function and structure independently of CHD 
and hypertension.  Since the first identification of cardiomyopathy, it was further divided 
in to two main types: (i) primary cardiomyopathy and (ii) secondary cardiomyopathy.  
(i) Primary cardiomyopathy refers to a defect in the heart tissue itself which subsequently 
aggravates the cardiac function. (ii) Secondary cardiomyopathy develops due to systemic 
syndromes which affects cardiac performance (Elliott et al, 2008).  
Cardiomyopathy can either lead to diastolic heart failure (preserved ejection fraction), or 
to systolic heart failure (reduced ejection fraction) (Paulus et al, 2007). The proposed 
mechanisms to explain these changes in the cardiac tissue include myocardial fibrosis 
and myocyte hypertrophy (Trachanas et al, 2014).   
Mechanism: Diabetes is associated with hyperglycemia and increased FFA production.  
Under hyperglycemic conditions, PKC and advanced glycation end products (AGEs) are 
upregulated, resulting in the development of fibrosis. Hyperglycemia can also lead to 
glucotoxicity due to increased ROS production (Boudina & Abel, 2007). In addition, 
pathways like the hexosamine biosynthetic pathway (HBP) may be activated, resulting in 
biochemical changes with possible detrimental effects including cell death.  
Increased FFAs activate the peroxisome proliferator-activated receptor alpha (PPAR-α) 
signalling pathway, which in turn, increases the transcription of several genes associated 
with fatty acid oxidation. PPAR-α increases pyruvate dehydrogenase kinase 4 (PDK4) 
expression, which downregulates pyruvate dehydrogenase (PDH) activity, consequently 
resulting in lactic acid accumulation and low glucose oxidation. In addition, PPAR-α 
activates malonyl-coenzyme A decarboxylase (MCD), thus restricting the conversion of 
acetyl-coenzyme A (AcCoA) to malonyl-coenzyme A (McoA). Downregulated McoA 
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levels lead to the activation of carnitine palmitoyl-transferase 1 (CPT1) in the 
mitochondria, which in response further initiates fatty acid oxidation (Boudina & Abel, 
2007). Once fatty acid oxidation in the mitochondria is increased, mitochondrial 
uncoupling and ROS generation from the electron transport chain, increase. Excessive 
ROS production in combination with high fatty acid levels result in lipotoxicity (Boudina & 
Abel, 2007).  
 
Glucotoxicity, fibrosis, mitochondrial uncoupling and lioptoxicity are all potential 
contributors to the development of a diabetic cardiomyopathy (Boudina & Abel, 2007).  
 
6. Overview on A-T and ATM 
 
6.1. A-T 
Ataxia telangiectasia (A-T) is a rare autosomal recessive disorder that progressively affects 
multiple organs causing severe disability. Ataxia, which refers to a lack of voluntary 
coordination and telangiectasia, to small dilated blood vessels, are both characteristics of 
the disease. A-T is caused by mutations in the Atm gene which consequently results in 
unstable and truncated ATM protein variants (Zhang et al, 1997). According to the National 
Ataxia Foundation (www.ataxia.org), the most common types of mutations that occur in the 
Atm gene are: frame shifting (25%), splicing (35%) and nonsensing (25%). 
6.2. Symptoms of A-T 
A-T emerges in the first 2 decades of life (Valentin-Vega et al, 2012). The first symptoms 
can usually be observed in early childhood when children begin to walk.  Unlike normal 
children of their age, these children wobble when they are walking, sitting or standing still. 
During late pre-school and early school A-T causes a gradual and continual loss of certain 
types of cells in the cerebellum of the brain.  Consequently these children develop difficulty 
with coordination and movement such as: oculomotor apraxia (difficulty in eye movement), 
swallowing complications, and inaccurate/unclear speech (National Ataxia Foundation - 
www.ataxia.org).   
The appearance of small dilated blood vessels covering the white of the eyes, the bridge of 
the nose, or the ears are all characteristics of A-T suffering individuals. Furthermore, A-T 
also weakens the immune system, causing A-T children to become more susceptible to 
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developing respiratory tract infections, including: sinusitis, pneumonia, ear infections and 
bronchitis (National Ataxia Foundation - www.ataxia.org).   
In addition, A-T prevents DNA repair, due to a lack of ATM protein which is responsible for 
recognising DNA breaks. As a result, these individuals are more prone to develop cancer, 
usually as lymphoma or leukemia (National Ataxia Foundation - www.ataxia.org).  
Previous studies linked ATM to the development of atherosclerosis in ApoE-/- mice 
(Sheneider et al, 2006). According to Mercer et al (2010), ATM haploinsufficiency results in 
the development of atherosclerosis in response to both the direct effects on the vessel wall, 
and the indirect metabolic effects.  
Lastly, ATM deficiency is closely related to the development of insulin resistance and 
ischemic heart disease. Individuals suffering from this disease have a very high (up to 49%) 
incidence of T2D and were found to die approximately 11 years earlier due to ischemic 
heart disease when compared to non-disease carriers (Su & Swift, 2000; Swift & Chase, 
1983). 
 
6.3. The ATM protein 
ATM is a 370 kDa serine/threonine protein kinase which contains an open reading frame of 
3056 amino acids (Abraham, 2001). ATM is believed to be closely related to the large 
protein family of Phosphatidylinositol 3-kinase-related kinases (PIKKs) as it displays the 
same homologies (Abraham, 2001). Proteins in the PI3K pathway play an important role 
especially in regulating cellular growth, proliferation, metabolism, protein synthesis and 
transcription (Cell Signalling (2014) – www.cellsignal.com). The ATM protein also has other 
sequences in its structure including: nuclear localization signals, HEAT rod-like helical 
structures for intracellular transport and a leucine zipper domain for the binding of DNA 
motifs. These sequences are characteristic in several nuclear and cytoplasmic proteins 
associated with protein trafficking (Yang et al, 2011). 
6.4. Functions of ATM 
According to Shiloh and Kastan (2001), less than 10% of the ATM protein functions can be 
attributed to its amino acid sequence, thus implying that more than 90% of this protein’s 
additional functions are still not yet identified.  This kinase was traditionally believed to be 
located only in the nucleus where it responds to genotoxic stress; however increasing 
evidence suggested that it might also be present and have significant functions in the 
mitochondria or in the cytosol of the cell (Abraham, 2001). 
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In the next section, the functions of ATM in the nucleus, mitochondria and cytosol of the cell 
are described respectively: 
6.4.1. Nuclear ATM  
Nuclear ATM (Figure 1.4) is recruited and activated by DNA double-strand breaks 
(Abraham, 2001). When activated, ATM consequently phosphorylates numerous proteins 
which in turn initiate the activation of the DNA damage response network (DNA repair, 
cell cycle arrest or apoptosis). Activated proteins include the cell cycle arrest checkpoint 
kinases (Chk-1 and Chk-2), tumor suppressor gene p53 and histone 2A gene (H2AX) 
(Canman et al, 1998; Banin, 1998).   
 
 
 
 
 
 
 
Figure 1.4: The activation of nuclear ATM via DNA breaks  
 
6.4.2. Mitochondrial ATM 
The smallest portion of ATM is localized to the mitochondria and is activated in response 
to mitochondrial dysfunction (Valentin-Vega et al, 2012). 
In thymocytes, a lack in mitochondrial ATM, as in individuals suffering from A-T, leads to 
the development of intrinsic mitochondrial abnormalities, including: increased ROS 
production, abnormal mitochondrial behaviour, increased cellular respiratory capacity 
and a reduction in mitophagy (Valentin-Vega et. al, 2012). It is suggested that ATM in the 
mitochondria plays a key role in regulating mitochondrial homeostasis (Valentin-Vega et 
al, 2012).  
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6.4.3. Cytosolic ATM 
The cytoplasmic functions of ATM are not yet fully determined. According to several 
studies, cytoplasmic ATM is predominantly found in neuronal or neuron-like cells (Oka & 
Takashima, 1998; Barlow et al, 2000; Boehrs et al, 2007).  A study done by Lim et al 
(1998), also suggested that cytoplasmic ATM is present in proliferating cells where it 
associates with a protein, b-adaptin, which is involved in vesicle trafficking.  
Importantly, especially with regards to our study, cytoplasmic ATM is also alleged to be 
involved in insulin signalling pathways, although the mechanism of action is still unclear 
(Yang & Kastan, 2000; Viniegra et al, 2005; Halaby et al, 2008).   
 
6.5. ATM and insulin signalling 
The association between ATM and insulin signalling is to date, not yet clearly established. 
The activity of ATM kinase was reportedly increased 3-fold in response to insulin 
stimulation. Furthermore, this observation was specifically seen in rat 3T3-L1 cells that had 
differentiated into adipocytes (Yang & Kastan, 2000).  
Insulin is assumed to phosphorylate the cytoplasmic translation repressor protein, 4EBP1 
(also called PHAS-I) via an ATM-dependent pathway (Figure 1.5). Under normal conditions, 
4EBP1 is bound to the eukaryotic translation initiation factor-4E (eIF-4E), thereby inhibiting 
it. When 4EBP1 is phosphorylated in response to ATM, it dissociates from eIF-4E, 
consequently initiating mRNA translation (i). Studies done by Yang and Kastan (2000) 
indicated that, in response to insulin stimulation, 4EBP1 is phosphorylated at specifically 
Thr36 and Thr45 residues via the PI3K/PKB/mTOR pathway or at Ser111 via ATM. In 
addition, ATM seemed to be only partially required for 4EBP1 release, which might also be 
interacting with the mTOR pathway to initiate the dissociation of 4EBP1 and eIF-4E 
efficiently (Yang & Kastan, 2000). 
According to more recent studies, the activation of ATM in response to insulin stimulation 
also (ii) phosphorylates PKB at Ser473, via an unknown phosphatase (Viniegra et al, 2005; 
Halaby et al, 2008). Once PKB is phosphorylated, it initiates multiple important physiological 
processes including: glucose uptake, protein translation, cell proliferation and also cell 
survival (Yang et al, 2011). However this mechanism is still vague and according to Yang et 
al (2011), it might be a good starting point to investigate the unknown functions associated 
with specifically cytoplasmic ATM and the A-T disease.  
Stellenbosch University  https://scholar.sun.ac.za
23 
 
Phosphorylated PKB in response, phosphorylates the (a) Tsc2-Tsc1 complex and (b) the 
AS160 protein. As mentioned in Chapter 1, Section 2.2.1, once the Tsc2-Tsc1 complex is 
phosphorylated, Rheb is stimulated, resulting in the activation of mTOR. Following this, 
mTOR can diverge into two different pathways to induce protein synthesis including: the 
activation of the 4EBP1 consequently resulting in the dissociation of eIF-4E or, the 
activation of p70s6k (Bevan, 2009).  PKB can also directly phosphorylate AS160, resulting in 
the association of AS160 at Thr642 with 14-3-3. Once bound to 14-3-3, a Rab binding 
domain is created which in turn converts Rab-GDP to Rab-GTP. In addition, GLUT4 vesicle 
translocation to the plasma membrane is initiated for optimal glucose uptake (Bevan, 2009).   
Furthermore, insulin stimulated activation of ATM also (iii) phosphorylates Liver kinase B1 
(LKB1), which in turn activates AMP-activated protein kinase (AMPK). LKB1 is an important 
kinase regulating (a) growth control (tumour suppressor) and (b) also cell polarity 
(Shackelford & Shaw, 2009). In addition, AS160 can also be phosphorylated via AMPK, 
which in turn also activates the translocation of GLUT4 vesicles to the plasma membrane 
(Cell Signalling (2013) - www.cellsignal.com).   
From the above, it is evident that ATM may play an important role in regulating insulin 
signalling via 4EBP1, PKB or LKB1 activation respectively, although these pathways have 
not been fully determined yet and has not been shown to be active in this context in the 
heart.  
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Figure 1.5:  ATM and insulin signalling  
6.6. ATM and insulin resistance 
A-T individuals display several symptoms associated with insulin resistance, including:  
glucose intolerance, hyperinsulinemia and hyperglycemia (Yang et al, 2011) which can 
subsequently lead to the development of insulin resistance and T2D. 
According to a study done by Schalch et al (1970), it was reported that 59% of A-T suffering 
individuals developed T2D. Since A-T individuals most likely die before T2D is fully 
diagnosed (Yang et al, 2011), the exact percentage of diabetic A-T individuals is difficult to 
determine. 
Recently, the effect of ATM deficiency on insulin resistance was investigated in 
apolipoprotein E (ApoE) null background mice. This atherosclerotic mouse model was 
cross-bred with Atm -/- and Atm +/- mice respectively (Schneider et al, 2006) whereafter 
they were fed a high fat diet (HFD) (Halaby et al, 2008) to induce insulin resistance. They 
found that ATM deficiency increased glucose intolerance, atherosclerosis and insulin 
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resistance (Schneider et al, 2006), thus indicating that ATM plays a crucial role in regulating 
insulin signalling.     
According to several other studies, individuals suffering from A-T also present with: lower 
IGF1R expression (Peretz et al, 2001), significantly increased circulating IGF-1 serum 
levels, and slightly increased serum IGF-binding protein (IGFBP)-3 levels (Busiguina et al, 
2000). In line with this finding, they also observed that A-T individuals have higher insulin 
levels in their blood, which can exacerbate the development of insulin resistance. 
When rats were fed a HFD to induce insulin resistance, it was observed that the expression 
of ATM dramatically decreased in skeletal muscle.  Insulin-stimulated phosphorylation of 
PKB at Ser473 and Thr308 in the muscle tissue was also attenuated, when compared to 
chow-fed controls (Halaby et al, 2008).  
Thus, one can propose that downregulated ATM levels, as seen in obese animals, are 
directly involved in the development of insulin resistance via the downregulation of PKB 
activation and consequently also GLUT4 translocation (Halaby et al, 2008).  
Since Ser473 is not an S/T-Q motif, ATM cannot directly phosphorylate PKB at this site (Kim 
et al, 1999; Golding et al, 2009). According to Golding et al (2009), it is speculated that ATM 
increased PKB phosphorylation by some unknown okadaic acid-sensitive phosphatase, like 
Protein phosphatase 1 (PP1) or Protein phosphatase 4-6 (PP4-6). 
Furthermore, ATM appears to indirectly regulate glucose homeostasis and the functions of 
insulin through a p53-dependent pathway (Ambrose & Gatti, 2013). Once ATM is activated, 
it phosphorylates the tumour suppressor p53, at Ser18 in mice (or Ser15 in human). In 
doing so, the transcriptional activity of p53 is activated. The inhibition of p53 Ser18 in mice 
resulted in the development of glucose intolerance and insulin resistance (Armata et al, 
2010). In light of the above, it can be suggested that ATM phosphorylation of p53 plays an 
important role in not only regulating cellular ROS levels but also controlling glucose 
homeostasis (Ambrose & Gatti, 2013).  
Taken together, insulin resistance in A-T individuals may develop due the either the lack of 
ATM to activate PKB at Ser473 or Thr 308 via some unknown ocadaic acid phosphatase, or 
to phosphorylate the tumour suppressor p53 at Ser15/18.  
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6.7. Activators & Inhibitors of ATM 
6.7.1 Activators 
ATM activators include:  (i) Insulin, (ii) Metformin and (iii) Chloroquine.  
Note: Only insulin was used as an activator of ATM (described in Chapter 1, Section 6.5) 
in this study, therefore activation with Metformin and Chloroquine will not be discussed in 
detail. 
 
(ii) Metformin  
Metformin is a well-known first-choice treatment for T2D (Nathan et al, 2009) as it has 
the ability to lower fasting glucose levels.  
Metformin surprisingly also activates ATM, however very little is known about the 
mechanism (Vazquez-Martin et al, 2011). According to a study done by Birnbaum & 
Shaw (2011), ATM becomes phosphorylated in response to metformin treatment. The 
activated ATM protein consequently results in the activation of AMPK directly or via 
LKB1, which in response, increases GLUT4 vesicle translocation and glucose uptake 
(Cell Signalling (2014) – www.cellsignal.com).   
(iii) Chloroquine 
Chloroquine is a well-known medication used for the treatment of malaria (Halaby et al, 
2013) and is currently also believed to improve insulin sensitivity and glucose tolerance 
potential (Emami et al, 1999; Halaby et al, 2013). According to Esposito & Sinden (1987) 
and Sogo et al, (1984) chloroquine has the ability to unwind the DNA double helix, 
resulting in restricted binding to nucleosomal linker regions; however the nucleosomes 
are not disrupted by chloroquine. As a result, alterations in the rotation angle between 
the adjacent nucleosomes occur, thereby affecting the higher-order chromatin structure 
formation (Krajewski, 2005). 
 
Recently is has been discovered that chloroquine might also be a potent stimulator of 
ATM. The exact mechanism of action is still unclear, however according to Kruit (2008) 
active ATM in response to chloroquine inhibits the c-Jun N-terminal kinase (JNK) 
pathway. Inactive JNK lowers the risk of developing atherosclerosis and insulin 
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resistance (Kruit, 2008). It is also possible that the unwinding of DNA may trigger ATM 
activity. 
 
6.7.2 Inhibitors 
(i) KU 55933/60019 
 
 
 
 
              Figure 1.6: KU 60019 structure 
KU 55933/60019 are both specific ATM kinase inhibitors. According to recent studies, KU 
55933 has the ability to radiosensitize human cancer cells. KU 60019 (Figure 1.6) shares 
the same pharmacological, structural and biological effects as KU 55933, although the 
KU 60019 analogue is improved to be 10 fold more effective to inhibit ATM 
phosphorylation in radiation-induced human glioma cells (Golding et al, 2009). In the 
same study done by Golding et al (2009), they tested the effect of 1 µM KU 60019 on 
229 kinases and observed that KU 60019 had no or a very little effect on these kinases; 
therefore they concluded that KU 60019 is specific to ATM inhibition. Furthermore the Ki 
1 nano Molar (nM) and IC50 (6.3 nM) values of KU 60019 are manipulated to be more 
than half of those of KU 55933.  
The half maximal inhibitory concentration (IC50) value is an important measurement 
to determine the effectiveness of a substance to inhibit a specific biological process or 
biological component (Pharmacelsus®). The inhibitor constant, Ki, indicates the 
potency of an inhibitor, thus the concentration required to produce half maximum 
inhibition (Enzyme inhibitors - http://www.ucl.ac.uk). 
KU 60019 mechanism: According to ApexBio Technology® (2013), KU 60019 inhibits 
ATM kinase directly; however the exact mechanism is still unknown but possibly the 
initial autophosphorylation event of activation of the kinase is inhibited as KU 60019 
leads to lower phosphorylated levels of ATM at Ser1981 (Bakkenist & Kastan, 2003).  
www.medchemexpress.co
m 
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According to Golding et al (2009), the more water-soluble KU 60019 effectively 
radiosensitized human glioma cells. A-T fibroblasts were not radiosensitized via KU 
60019 which might be an indication that ATM kinase is target specific. KU 60019 also 
reduced the phosphorylation of basal Ser473 PKB, thus speculating that ATM might 
activate a protein phosphatase that dephosphorylates PKB (Golding et al, 2009).  
Furthermore, KU 60019 inhibits the migration and invasion (in vitro) of glioma cells which 
could be an indication that glioma growth/motility is controlled by ATM via PKB. It is also 
suggested that KU 60019 interferes with prosurvival signalling pathways as it had no 
further radiosensitizing effects on PKB and MEK inhibited treated cells (Golding et al, 
2009). 
Thus in summary, KU 60019 reduces ATM phosphorylation at Ser1981 and PKB 
phosphorylation at Ser473, inhibits the DNA damage response mechanism and, 
radiosensitizes and inhibits the migration and invasion of certain cells (Golding et al, 
2009). 
6.8. Link between ATM & CVD 
CVDs refer to several disorders of the heart and blood vessels. According to the WHO 
(2015), CVDs are the main cause of death globally. In 2012, a projected 17.5 million 
individuals died from CVDs globally, whereas the greater number of these deaths was 
due to stroke (6.7 million) and coronary heart disease (7.4 million).  
Cardiomyocyte apoptosis regulates both functional and structural aspects of the heart, 
mainly during remodelling and/or growth (Foster et al, 2011). 
Once the β-adrenergic receptor (β-AR) in the heart is stimulated in response to 
isoprenaline or noradrenaline, the ventricular contraction in the heart increases due to 
increased calcium release (Yano et al, 2005). However overstimulation of these 
receptors results in cardiomyocyte apoptosis initiation through numerous pathways. One 
of the pathways results in the activation of JNK and stabilization of p53, both of which are 
targets of ATM. Another β-AR target is PKB, which is part of the anti-apoptotic pathway 
(Freemantle et al, 1999). 
Although the mechanism of how ATM affects the cardiovascular system is still vague, 
Foster et al (2011) demonstrated that ATM KO mice structurally displayed a reduction in 
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septal wall thickness and functioning of the left ventricular parameters. ATM KO mice 
also exhibited increased cardiac hypertrophy and fibrosis.  
Cardiac hypertrophy is an adaptive response and refers to thickening of the heart 
muscle (myocardium) consequently reducing the ventricular space. It is mainly caused by 
hypertension or heart valve stenosis (Nature (2015) – www.nature.com).  
Fibrosis refers to the development of fibrous connective tissue as a response 
mechanism to repair injured or damaged tissue. Fibrosis arises especially when the heart 
is damaged as a result of myocardial infarction, which consequently results in the 
stiffening of the heart muscle and valves. This decrease in flexibility can increase the risk 
of heart failure and valvular dysfunction (Robertson, 2014). 
ATM KO mice furthermore displayed upregulated connective tissue growth factor 
(CTGF), plasminogen activator inhibitor-1 (PAI-1) and matrix metalloproteinase (MMP)-2. 
CTCF is believed to induce fibrosis in the heart tissue whereas PAI-1 is a risk factor for 
thrombosis and atherosclerosis development. MMP-2 levels are normally upregulated in 
response to heart failure and results in cardiac rupture (Foster et al, 2011). 
In ATM heterozygous KO animals, apoptosis is triggered in response to β-AR stimulation, 
whereas in ATM wild type (WT) animals β-AR-triggered apoptosis is prevented (Foster et 
al, 2011). In addition, ATM expression increased upon β-AR stimulation, which 
consequently inhibited ventricular fibrosis and remodeling. Thus, a decrease in cardiac 
ATM expression results in increased myocyte apoptosis (Gorr et al, 2012), causing 
fibrosis and hypertrophy. Foster et al (2011) furthermore claimed that myocyte apoptosis 
in ATM deficient animals is due to the decreasing activity of PKB, rather than through the 
JNK/p53 pathway.  
From the above it is evident that the complete mechanism and link between ATM and the 
heart is not yet fully understood. It is however clear that ATM is crucial for the activation 
of the anti-apoptotic PKB pathway to prevent the development of cardiovascular 
diseases. 
 
 
7. Motivation for the study 
 
In 2014, 40% men and 70% women were already suffering from being overweight or obese in 
South Africa (Baleta & Mitchell, 2014) mostly due to high levels of carbohydrate consumption as 
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a result of poor financial support (Goedecke et al, 2006). Obesity is associated with the 
development of insulin resistance, which, in turn, is positively correlated with the risk of CVD 
development. In 2014, the International Diabetes Federation stated that 22.7 million South 
Africans are suffering from diabetes. Diabetic cardiomyopathy is a condition where T2D affects 
the cardiac function and structure independently of CHD and hypertension (Rubler et al, 1972). 
A-T patients display a very high incidence of insulin resistance or T2D (Yang et al, 2011) and are 
also more susceptible to ischaemic heart disease. Furthermore, ATM expression was a found to 
be downregulated in obese/insulin resistant animals (Halaby et al, 2008).   
ATM is expressed in the heart but it is currently unknown whether it is involved in insulin 
signalling in the heart, or whether it is in any way involved in the development of a 
cardiomyopathy.   
Up to date it is not yet established where in the insulin signalling cascade this protein may fit in 
and what pathways it may affect or not.  Previous studies linked ATM to glucose uptake, the 
activation of AMPK (Shackelford & Shaw, 2009) and PKB (Viniegra et al, 2005), and the 
development of atherosclerosis in ApoE-/- mice (Sheneider et al, 2006); however none of these 
have been investigated in the heart.  
If the relationship claims between ATM and insulin resistance is validated by the present study, 
ATM can be an effective and alternative therapeutic target to treat the increasing amount of 
South Africans suffering from obesity-induced T2D. 
 
8. Aim and Objectives 
Aim: To determine the importance of ATM in glucose uptake in cardiomyocytes prepared from 
control vs. obesity-induced insulin resistant animals. 
Objective 1:  To determine ATM levels in rat models of obesity-induced insulin resistance and 
characterized a suitable model for the study. 
Objective 2: To manipulate the ATM protein in isolated cardiomyocytes from both obese, insulin 
resistant rats and their age-matched control groups with suitable activators or inhibitors of ATM 
and measure 2DG uptake, expression and activation of intermediates of the insulin signalling 
pathway (IRS1, PI3K, PTEN, PKB, AS160, AMPK, GSK-3β) and GLUT4 expression. 
We only investigated cytosolic ATM, and not ATM present in the nucleus or in the mitochondria. 
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CHAPTER 2: MATERIALS AND METHODS 
1. Animals 
40 Male Wistar rats of the same age and initial weights of 190 ± 10 grams (g) were used in this 
study. The animals were divided randomly into two groups. Group one was fed a HFD containing 
11.5 % fat while group two, the age-matched controls received normal rat chow (4.8 % fat) for a 
period of 16 weeks. The animals had free access to food and water and kept on a 12-hour 
day/night cycle in the Central Research Facility of the Faculty of Health Sciences of the 
University of Stellenbosch.  
The study was registered at the Committee for the use of animals in research of the University of 
Stellenbosch (Number SU-ACUM12-00040) and conducted under the revised South African 
National Standard for the Care and Use of Animals for Scientific Purposes (South African 
Bureau of Standards, SANS 10386, 2008). 
 
2. Diet compositions  
The Table below (Table 2.1) indicates the two different diet compositions which were fed to the 
animals over the 16 week period. The HFD was prepared by adding Holsum cooking fat to the 
diet-induced obese (DIO) diet (Salie et al, 2014). The DIO diet consisted of standard rat chow as 
described by Pickavance et al (1999) with additional sucrose and condensed milk (Ruduwaan et 
al, 2014). We only used the HFD in our study to induce obesity related insulin resistance. 
Table 2.1: Different diet compositions (Control vs. HFD) 
 
 
3. Oral Glucose Tolerance Test (OGTT) & Glucose measurement 
 
OGTT’s are used as a central marker in the determination of insulin sensitivity. In this study, 
OGTT’s were performed in week 15 after the animals were fasted overnight. For ethical 
purposes, the animals were injected with 0.1 microliter (µl) Eutha-naze (53 mg/kg Sodium 
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pentobarbital) to create an anaesthetic environment throughout the procedure. Using a 
glucometer, the basal glucose level for each rat was taken by collecting a drop of blood after a 
tail prick. This was followed by gavaging 1 milligram (mg)/kg sucrose to each animal, where after 
their blood glucose levels were monitored constantly for 2 hours. The blood glucose level for 
each rat was measured at 3 minutes (min), 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 45 
min, 60 min, 90 min and 120 min respectively using a glucometer and a drop of blood from the 
same tail prick. The animals were left to recuperate from the metabolic insult for a week before 
experimentation. 
 
4. Biometric measurements and sacrificing of animals 
After 16 weeks, the body weight of each animal was determined just before sacrificing. The 
animals were sacrificed by injecting them with 0.5 µl Eutha-naze (265mg/kg Sodium 
pentobarbital). A foot-pinch test (pedal reflex) was performed to be assured that the animals 
showed no response before opening the chest cavity and removing the heart. Following this, the 
intra-peritoneal fat (IP fat) of each animal was removed and weighed. 
 
5. Biochemical analysis 
 
5.1. Blood collection 
Blood collection entailed the withdrawal of 1 millilitre (ml) blood directly from the carotid 
artery from control and HFD anaesthetized overnight fasted animals respectively at the time 
of the OGTT in week 15. The blood of each animal was transferred to a SGVac gel tube and 
left on ice for 20 min. Following this, the blood samples were centrifuged at 3000 revolutions 
per minute (rpm) for 10 min.  
The blood serum was removed and stored at -80 degree Celsius (ºC). The remaining blood 
(white blood cells, platelets, red blood cells) was discarded. 
 
5.2. Insulin assay 
For the determination of insulin levels, a commercially available EMD Millipore Corporation 
Enzyme-linked immunosorbent assay (ELISA) was used. All the reagents were pre-warmed 
to room temperature (25ºC). Control and HFD serum samples were analysed in duplicate for 
the determination of insulin levels. This non-radioactive quantification assay contained an 
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anti-rat insulin antibody coated 96-well microplate and all relevant reagents were supplied by 
the assay kit.  
The required number of wells for all the blank, standard, quality control (QC) and serum 
samples were washed 3 times with 300 µl 10X diluted Wash buffer, where after the residual 
fluid in the wells were decanted. Following this, 10 µl Assay buffer (0.05 Molar (M) 
phosphosaline, pH 7.4, containing 0.025 M EDTA, 0.08% Na-azide and 1% Bovine serum 
albumin (BSA)) was added to each blank and sample well and 10 µl Matrix solution (charcoal 
stripped pooled mouse serum) was added to the blank, standard and QC wells.   
Following this, the standards (10 µl/ml, 5 µl/ml, 2 µl/ml, 1 µl/ml, 0.5 µl/ml, 0.2 µl/ml, 0 µl/ml) 
were prepared in duplicate. In the order of ascending concentration 10 µl of each standard 
was pipetted into the respective wells and 10 µl of the two QC samples were added to their 
appropriate wells. Following this, 10 µl serum of both the control and HFD animals were 
added sequentially in duplicate to the remaining wells.   
80 µl rat pre-titered biotinylated anti-insulin Detection antibody was added to all the 
standards (including the blank and QC samples) and the serum samples followed by an 
incubation period of 2 hours at room temperature on slow rotator (400-500 rpm). During 
these 2 hours, insulin present in the standard and serum samples bound to the wells. All the 
fluid was decanted and the wells were washed thoroughly with 300 µl 10X Wash Buffer. 100 
µl pre-titered Streptavidin- Horse Radish Peroxidase (HRP)-conjugate in buffer was pipetted 
to each well and incubated for 30 min at room temperature to visualize the target molecule, 
insulin. After washing the wells again 3 times with 300 µl 10X Wash Buffer, 100 µl 3,3',5,5'-
Tetramethylbenzidine (TMB) One-Step Substrate Reagent was added to each well and 
incubated for 15 min at room temperature.  TMB is a specific reagent which has the ability to 
act as a hydrogen donor in response to the reduction of hydrogen peroxide to water by HRP 
enzymes. Consequently the resulting diimine causes a blue colour development in proportion 
to the amount of insulin bound. 100 µl 0.3 M Stop Solution was pipetted into each well. This 
sulphuric acid solution changed the blue colour to a yellow colour. The intensity of the colour 
was immediately measured within 5 min on a microplate reader at 450 nanometres (nm) and 
590 nm respectively.   
A 4-parameter logistic equation dose-response curve was set up by plotting the absorbance 
unit of 450 nm less that of 590 nm, on the Y-axis against the rat insulin standard 
concentrations on the X-axis. The increase in absorbance is directly proportional to the 
amount of insulin measured in the unknown serum samples; therefore the curve was set up 
by known standard insulin concentrations where after it was used as a reference for the 
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determination of the samples of interest. An online ELISA analysis program 
(http://www.elisaanalysis.com) was used to set up the curve and calculate the insulin levels 
of the control and HFD serum samples. The assay was only accepted if the QC values fell 
within the calculated QC range (EMD Millipore Corporation).  
 
5.3. HOMA IR index calculation 
The Homeostasis model assessment of insulin resistance (HOMA IR) index was an 
assessment method used to quantify insulin resistance in the different groups. The HOMA IR 
index was calculated using the following formula:  
HOMA IR index = Basal glucose levels (mmol/L) x Fasting insulin levels (mIU/ml)/22.5.  
 
6. Ventricular cardiomyocyte preparation  
 
Adult ventricular cardiomyocytes from the control and HFD animals were prepared in our 
laboratory by collagenase perfusion, essentially as described by Fischer et al (1991) and 
subsequently modified in our laboratory (Huisamen et al, 2001). The collagenase used in this 
study, was previously tested in our laboratory to give a yield of ~ 80% rod-shape myocytes 
(Huisamen et al, 2008).  
After 16 weeks, animals were fully anaesthetized as described in Chapter 2, Section 4, 
whereafter their hearts were removed and placed in ice-cold Krebs-Henseleit buffer (119 mM 
NaCl; 24.9 mM NaHCO3; 4.74 mM KCl; 1.19 mM KH2PO4; 0.6 mM MgSO4.7H2O; 0.59 mM 
Na2SO4; 1.25 mM CaCl2.12H2O and 10 mM glucose). The isolated hearts were cannulated via 
the aorta onto the perfusion system, whereupon it was retrogradely perfused with a Ca2+ free 
HEPES buffer (“Solution A” containing: 6 mM KCl; 1 mM NaHPO4; 0.2 mM NaH2PO4; 1.4 mM 
MgSO4; 128 mM NaCl; 10 mM HEPES; 5.5 mM D-glucose and 2 mM pyruvate, pH 7.4) at 37ºC 
for 5 min.  
Why Ca2+ free buffer? According to Zimmerman et al (1967), Ca2+ depletion leads to minimal 
ultrastructural changes in cells, however when Ca2+ is reintroduced, it results in the 
hypercontraction of the cells. Previous studies (Muir, 1967; Yates & Dhalla, 1975; Ashraf, 1979; 
Frank et al, 1982) indicated that during Ca2+ free circumstances, the intercalated discs in the 
muscle tissue are becoming partly separated due to the dissociation of the cadherin complexes. 
Furthermore, the glycocalyx covering the plasma membrane also vanishes in response to 
downregulated Ca2+ conditions. These conditions therefore allow dissociation of myocytes from 
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each other. If Ca2+ is rapidly reintroduced in the uncoupled adjacent cells, it results in contractile 
activation, which disrupts the weakened cell-cell contact sites. The cells will therefore rupture 
and terminal Ca2+ overload will result in hypercontracture (Piper, 2000). 
The hearts were continuously gassed with 100% oxygen (O2) throughout the perfusion 
procedure. Following this, the hearts were perfused for 15 min (3   C) in a re-circulating manner 
with a HEPES digestion buffer (“Solution B” containing: “Solution A” + 0. % fatty acid free BSA + 
1 mg/ml Worthington Collagenase Type II + 18 mM 2,3-butanedione monoxime (BDM)).  
BDM is an ATPase inhibitor preventing the activation of the myosin protein and crossbridge 
formation for contraction.  
To prevent Ca2+ overload, Ca2+ levels were increased slowly by the addition of 50 μl CaCl2 (100 
µM) after exactly 20 min and 25 min of the total perfusion time. As soon as the perfusate 
changed from a dripping to a continuously free flowing state, the heart was fully digested. The 
digested hearts were detached from the perfusion system, followed by the removal of the 
ventricles from the atria and connective tissues.   
The ventricular tissues were torn apart and incubated in 50 ml post-digestion buffer (“Solution C” 
containing: 50% of “Solution A” + 50% of “Solution B” + 1% BSA + 1% fatty acid free BSA + 0.2 
mM CaCl2) for a period of 15 min under 100% O2 in a shaking water bath (180 strokes/min at 
37ºC). After 15 min of incubation, CaCl2 was added respectively on 15 min, 16 min, 17 min, 18 
min and 19 min to the ventricular heart tissue to reach a final concentration of 1.25 mM (4 x 100 
µl CaCl2
 
and 1 x 125 µl of a 100 mM CaCl2 solution). The tissue was then filtered through a 200 x 
200 μm nylon mesh and gently centrifuged at 100 rpm for 3 min. The supernatant was aspirated 
and the pellet was resuspended in 35 ml Solution D (“Solution D” containing: “Solution A” + 2% 
fatty acid free BSA + 1.25 mM CaCl2) for 5 min. This resuspension step was important to assure 
that the cells settle under gravity through the 2% BSA solution into a loose cell pellet. As only the 
viable cardiomyocytes will settle, the supernatant, containing the dead/dying cells, was once 
again aspirated. The cell pellet was resuspended in 15 ml fresh Solution D, where after which it 
was left on a slow rotator (30 rpm), under O2, at room temperature for 1 hour to stabilize. After 
stabilization, the cells were allowed to settle under gravity for 5 min. The supernatant was gently 
aspirated and the cells were resuspended in 6 ml Solution E (“Solution E” containing: “Solution 
A” minus D-glucose and pyruvate + 2.0% fatty acid free BSA + 1.25 mM CaCl2), and spun down 
at 100 rpm for 3 min. This washing step was repeated 3 times (the supernatant was discarded 
after every wash) with 6 ml fresh Solution E. After the last wash, the pellet was suspended in a 
suitable volume of Solution E. The volume depended on the number of conditions to be tested 
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for the determination of (a) 2DG uptake and (b) Western blotting experiments as described in 
Chapter 2, Section 7 and Section 8 respectively.  
The HEPES, BDM, D-glucose as well as the Na-pyruvate were purchased from Sigma-Aldrich 
(St Louis, MO), the Worthington Collagenase Type II was obtained from Worthington 
Biochemical Corporation (Lakewood, NJ) and both BSA’s were purchased from Roche (Cape 
Town). 
 
7. 2DG uptake by cardiomyocytes 
 
2DG refers to a glucose molecule which can be taken up but not metabolized, because it has a 
hydrogen molecule instead of a 2-hydroxyl group at position C2 of its structure (Figure 2.1).  
 
 
 
 
Figure 2.1: Glucose vs. 2DG structure 
2DG uptake by the cardiomyocytes was measured at different insulin concentrations (Chapter 2, 
Section 7.1) and with different activators (Chapter 2, Section 7.2) in combination with inhibitors 
as described below: 
Note: The insulin dosage response experiment as described in Chapter 2, Section 7.1 was 
conducted on young control (250 g weight animals), age-matched control and HFD animals. 
 
7.1.  2DG uptake at different insulin concentrations 
 
500 µl cardiomyocytes (approximately 0.5 mg protein), as prepared in Chapter 2, Section 6, 
was suspended in different volumes oxygenated Solution E for each variable (Basal, 
Phloretin, 1 nM insulin (INS 1), 10 nM insulin (INS 10), 100 nM insulin (INS 100)). 50 µl 
Phloretin (final concentration 400 µM) was added to the Phloretin samples only for the 
measurement of non-carrier mediated glucose uptake (Table 2.2). 
 
(i) Insulin was serially diluted before experimentation: 
INS 100:       450 µl Solution E + 50 µl insulin stock [10 µM to 1µM]  
www.nature.com 
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INS 10:      450 µl Solution E + 50 µl 1 µM [to 100 nM insulin]  
INS 1:      450 µl Solution E + 50 µl 100 nM [to 10 nM insulin]  
 
(ii) The 2DG and Phloretin were prepared as follow: 
2DG:  290 µl Deoxy-glucose (45.6 mM stock solution) + 10 µl radioactive 
(tritiated) Deoxy-glucose    
Phloretin:  450 µl Solution E + 50 µl Phloretin stock [64 mM stock solution in DMSO] 
Insulin, Deoxy-glucose and Phloretin were purchased from Sigma-Aldrich (St Louis, MO), 
radiolabelled 2DG was purchased from PerkinElmer South Africa (Pty) Ltd. 
  
Table 2.2: Assay for the determination of 2DG uptake at different insulin concentration (INS 
1, 10, 100) 
 
All the cells were incubated at 3   C in a shaking water bath (180 strokes/ min), where 75 µl 
INS 1, INS 10 and INS 100 as prepared in Chapter 2, Section 7.1(i) were respectively added 
after 5 min to the corresponding insulin samples (Figure 2.2). After 20 min, glucose uptake 
was initiated by the addition of 25 µl 2DG as prepared in Chapter 2, Section 7.1(ii) (1.5 
µCuries(Ci)/ml; final 2DG concentration 1.8 µM) to all of the samples. At this low 
concentration of 2DG, the kinetics of uptake of 2DG is equivalent to that of glucose and can 
therefore be used as a measure of glucose movement into the cell. At higher concentrations, 
this presumption is not valid, because 2DG at higher concentrations slows the glycolytic 
process and therefore glucose uptake. 2DG glucose uptake was also shown to be linear 
under these conditions for up to 60min (Fischer et al, 1991). 
After 30 min, glucose uptake was terminated by the addition of 50 µl Phloretin (400 µM) to all 
the samples (except the Phloretin samples). 
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Figure 2.2: 2DG uptake protocol in response to insulin stimulation (INS 1, 10, 100 nM) 
The cells were transferred into Eppendorf tubes and spun down at 14 500 rpm for 90 
seconds (sec). The pellets were washed twice with 450 µl HEPES buffer and dissolved in 1 
N NaOH. After the pellets were dissolved, an equal volume of distilled water (dH2O) was 
added to render a concentration of 0.5 NaOH where after the samples were used for (a) 
Lowry (Lowry et al, 1951) protein determination and (b) counting of accumulated radio-
activity using a scintillation counter. 
(a) Lowry protein determination 
The Lowry method is a well-known colorimetric assay which entails the interaction of the 
proteins in the samples with an alkaline copper tartrate (Na-K-Tartrate-CuSO4) and Folin 
Ciocalteus reagent. Colour development can be visualized when the protein and copper 
complex in the alkaline buffer is formed, and secondly when a reduction reaction caused by 
Folin Ciocalteus leads to a spectral shift from 405 nm to 750 nm (Lowry et al, 1951).  
BSA standards were prepared as follow from a BSA solution with known concentration 
determined spectrophotometrically by determining the OD at 280 nm and using the albumin 
extinction coefficient of 1.51: 
Standard 1: 1 ml undiluted BSA in 200 ml 0.5 NaOH.  
Standard 2: 2 ml undiluted BSA in 200 ml 0.5 NaOH. 
Standard 3: 2 ml undiluted BSA in 100 ml 0.5 NaOH. 
The concentration of these standards were then also determined accurately. 
In the assay, 50 µl of 0.5 N NaOH was added to the first Luckham tube and served as a 
blank. Following this, 50 µl of each three BSA standards and samples (in triplicate) were 
pipetted into the rest of the Luckham tubes. Next, 1 ml Na-K-Tartrate-CuSO4 containing: 0.5 
ml 2% Na-K-Tartrate, 0.5 ml 1% CuSO4.5H2O and 49 ml 2% Na2CO3, was added to each 
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tube with time intervals of 10 sec between tubes. After 10 min of the first addition of Na-K-
Tartrate-CuSO4, 100 µl Folin C (2 ml Folin-Ciocalteu in 4 ml dH2O) was added to each tube 
with time intervals of 10 sec between tubes. After every addition, the tubes were vortexed. 
The tubes were left on the bench for 30 min for optimal reaction, whereafter the OD values 
were read at 750 nm in a spectrophotometer. A standard curve was set up in Excel by 
plotting the OD absorbance values on the Y-axis and the standard protein concentration 
values (mg/ml) on the X-axis. Using the standard curve, the total amount of protein (mg/ml) 
in each sample was determined.  
(b) 2DG uptake 
To determine the amount of radioactivity associated with the cells, 100 µl of each sample in 
duplicate was added to 3 ml scintillation fluid. We also respectively prepared a blank tube 
containing only scintillation fluid and a radioactive total counts tube containing 25 µl 2DG (as 
prepared in Chapter 2, Section 7.1(ii)) and scintillation fluid. All the samples were kept 
overnight in a sealed dark area to minimize chemiluminescence produced by adding the 
alkaline solution to the scintillation fluid. The total radioactivity was counted in a scintillation 
counter (Beckman®) beforehand to determine the specific activity of the 2DG solution. 
Following this, all samples were counted in disintegrations per minute (DPM). Using the total 
protein values (mg/ml) calculated from the Lowry method, and the DPM values from the 
scintillation counter, 2DG uptake was calculated and expressed in picomol (pmol) 2DG/mg 
protein/30min. Lastly, the the average of the Phloretin samples in pmol 2DG/mg 
protein/30min was subtracted from each sample to correct for background data. Phloretin 
inhibits all carrier mediated (GLUT1 and GLUT4) glucose uptake, but there is always residual 
glucose entering the cell, especially through the fructose transporters (Fischer et al, 1991). 
 
INS 10 was used for the following experiments due to its optimal glucose uptake stimulatory 
capacity. However INS 10 is still a physiological concentration and it will allow any additive 
responses to be visible, whereas INS 100 is a pharmacological concentration, and it will elicit 
a maximal response that will mask any additive effect of the substrates used. 
 
7.2. 2DG uptake determination with activators and inhibitors  
The same procedure as described in Chapter 2, Section 7.1 was followed for 2DG uptake 
determination, but in combination with activator INS 10 and inhibitors WM (100 nM) and KU 
60019 (3µM) (Table 2.3). Phloretin was once again added to the Phloretin samples only 
before experimentation in the water bath started.  
Stellenbosch University  https://scholar.sun.ac.za
40 
 
(i) Preparation of activators and inhibitors: 
INS 10 and Phloretin as prepared in Chapter 2, Section 7.1(i) and (ii) respectively, was used. 
WM (100 nM):  9990 µl Solution E + 10 µl WM stock [2mM] 
KU 60019 (3µM):  990 µl Solution E + 10 µl KU 60019 stock [9mM] 
WM was obtained from Sigma-Aldrich (St Louis, MO) and KU 60019 was obtained from 
Selleck Chem. 
Table 2.3: Assay for the determination of 2DG uptake with different activator and inhibitors 
 
 
 
 
After 5 min of incubation at 3   C in a water bath (1 0 strokes  min) the two inhibitors (WM or 
KU 60019) were added to the specific cardiomyocytes, followed by the addition of INS 10 to 
the insulin samples (INS 10, WM & INS 10, KU60019 & INS 10) after an additional 15 min 
(Figure 2.3). 2GD (as prepared in Chapter 2, Section 7.2(i)) was added at 35 min to initiate 
glucose uptake in the cells followed by the addition of Phloretin (as prepared in Chapter 2, 
Section 7.1(ii)) at 65 min to terminate the process.  
Figure 2.3: 2DG uptake protocol with different activators/inhibitors 
As described in Chapter 2, Section 7.1 the cells were spun down in Eppendorf tubes, 
washed, and the pellets dissolved in 1N NaOH. The samples were then used for Lowry 
(Lowry et al, 1951) protein and radiolabel determination and 2DG expressed in pmol 
2DG/mg protein/30 min. Lastly, the the average of the Phloretin samples in pmol 2DG/mg 
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protein/30min was subtracted from each sample to correct for background non-carrier 
mediated 2DG uptake. 
 
 
8. Western Blotting  
Western blotting was conducted on cardiomyocytes from both the control and HFD animals to 
determine the expression and activation of certain proteins in the insulin signalling pathway. 
After the animals were sacrificed, as described in Chapter 2, Section 4, cardiomyocytes were 
prepared as described in Chapter 2, Section 6. The cardiomyocytes were then manipulated with 
INS 10, WM and KU 60019 respectively as presented in Figure 2.3; however at 35 min, Phloretin 
was added instead of 2DG as described in Chapter 2, Section 7.1 & 7.2. After the addition of 
Phloretin, the cells were directly placed on ice to stop all further reactions and spun down at 
14 500 rpm for 90 sec. The supernatant was removed and the cells were washed twice with 450 
µl HEPES buffer. The pellets were used for lysate preparation as described in the following 
Section. 
8.1. Sample preparation (lysate) 
For lysate preparation, the proteins of interest were extracted by the addition of 100 µl lysis 
buffer to each cell pellet (two volumes of lysis buffer for one volume of cells). The lysis buffer 
contained: 2 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 150 mM NaCl, 1 mM β-
glycerophosphate, 2.5 mM tertasodiumpyrophosphate, 1 mM Na3VO4, 1% Triton X-100, 10 
μg ml leupeptin, 10 μg ml aprotinin and 50 μg ml PMSF.   
Following this, 0.15 millimetre (mm) zirconium oxide beads purchased from Next Advance, 
were added to each sample (amount of beads added were equal to the pellet size). The 
samples were homogenized at speed 8 in the Bullet Blender™ for 4 min, where after it was 
left on ice for 20 min to allow for optimal reaction with the lysis buffer.  
After 20 min, the samples were centrifuged at 15 000 rpm for 20 min (4  C). The supernatant 
of each sample was pipetted in to Eppendorf tubes. Using the Bradford method (Bradford, 
1976), the amount of protein in each sample was determined as follows: 
The supernatant of each sample was diluted (a) 1:10 (45 µl dH2O and 5 µl supernatant). The 
samples were further diluted (b) 1:20 (5 µl of the diluted supernatant (a) and 95 µl dH2O). 
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The Bradford assay was set up as indicated below: 
 The standards in duplicate:          0  (100 µl dH2O) 
5  (5 µl diluted BSA & 95 µl dH2O) 
10  (10 µl diluted BSA & 90 µl dH2O) 
20  (20 µl diluted BSA & 80 µl dH2O) 
40  (40 µl diluted BSA & 60 µl dH2O) 
60  (60 µl diluted BSA & 40 µl dH2O) 
80  (80 µl diluted BSA & 20 µl dH2O) 
(Note: 1:4 Diluted BSA = 100 µl BSA stock solution & 400 µl dH2O) 
 Diluted samples in duplicate (b):  5 µl of diluted sample (a) & 95 µl dH2O 
The Bradford solution, containing: 0.6 mM Coomassie Brilliant Blue G-250, 95% ethanol and 
50% (v/v) phosphoric acid was diluted 1:5 with dH2O followed by filtration through a double 
layer of Whatman filter paper. 900 µl of this diluted Bradford reagent was added to the 
standards and duplicated samples. The colour changed from a red colour to a blue colour 
under acidic conditions in the standards and duplicate samples, where after the absorbance 
was measured at 595 nm in a spectrophotometer. Under the assay conditions, the 
Coomassie blue bound to protein with a colour development linear to protein concentration at 
low protein levels.  
The standard curve was set up by calculating the mean of the duplicate standard values 
(mean OD values) using Excel. The protein (µg) values were plotted on the X-axis against 
the mean OD values on the Y-axis. Using the standard curve, the amount of protein, lysis 
buffer and Laemmli sample buffer (Laemmli, 1970), that must be added to each sample, to 
ensure that an equal amount of protein per volume unit used was calculated. 
850 µl Laemmli sample buffer (4% SDS, 20% glycerol, 10% 2-mercaptothanol (2-ME), 
0.0004% bromophenol blue and 0.125 M Tris-HCl) was diluted with 150 µl 2-ME before it 
was added to the lysates.  After the lysates were prepared using the calculated values, the 
samples were boiled for 5 min and the aliquots were stored at -80°C. 
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8.2. Protein separation  
Once again, all the stored samples were boiled for 5 min followed by 5 min of centrifuging at 
5000 rpm.  An equal amount of protein of each sample was loaded per well in the gel using a 
Hamilton syringe purchased from Sigma-Aldrich (St Louis, MO). 
Sample loading:  
Positive control: A lysate from a 7-8 week old untreated control rat heart was prepared to 
serve as the positive control in the study. The same positive control was loaded on to each 
gel to enable data from one blot to be compared to any other blot. All the samples were 
always normalized to this positive control. The control and HFD gels were loaded as follow: 
Control: Marker, Positive control, 2 x Controls, 2 x INS 10, 2 x WM, 2 x INS 10 + WM, 2 x 
KU 60019, 2 x INS 10 + KU 60019.  
HFD: Marker, Positive control, 1 x Control, 2 x HFD Controls, 2 x INS 10, 2 x WM, 2 x INS 10 
+ WM, 2 x KU 60019, 2 x INS 10 + KU 60019. 
To compare the HFD blots with the control blots, a basal age-matched control sample was 
loaded on to the HFD blot. Thus, the HFD values could be calculated as a ratio to the control 
value.  
Three different gel preparation techniques were used in the study due to the incorporation of 
new stain-free techniques in our laboratory and also due to ATM and IRS1 having large 
molecular sizes of 370 kDa and 180 kDa respectively. 
  
(i) Standard gel preparation 
 
Different percentages of polyacrylamide running gels (7.5%, 10% & 12%) with 4% stacking 
gels were prepared for the separation of the proteins in the samples as indicated in Table 
2.4. To identify the molecular weights of the proteins of interest, 5 µl of the protein ladder, 
obtained from Thermo Scientific was loaded as a marker in the first well of the 
polyacrylamide gel. The boiled and centrifuged samples were loaded in the following wells 
and the gel compartment tank was filled with running buffer. The running buffer contained: 50 
mM Tris, 384 mM glycine and 1% SDS, pH 8.3.  The polyacrylamide gels were subjected to 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) for 10 min at 100V, 
200mA followed by 50 min at 200V, 200mA. After 60 min, the separated proteins within the 
polyacrylamide gels were transferred for 1 hour at 200V, 200 mA, to polyvinylidene fluoride 
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(PVDF) membranes (ImmobilonTM P, Millipore), in a transfer buffer filled tank. The transfer 
buffer contained: 25 mM Tris, 192 mM glycine and 20% methanol, pH 8.3. 
Once the transfer period was finished, the membranes were placed in fresh methanol for 30 
sec and left to air dry for 15 min.  The dry membranes were then immersed in reversible 
Ponceau red staining (5% Ponceau Red in acetic acid) for 2 min to visualize whether the 
proteins did transfer from the polyacrylamide gels to the membranes. 
The membranes were washed thoroughly with a TBS-Tween solution (Tris-buffered saline 
(TBS) + 0.1% Tween 20) for 30 min (3 x 10 min) on a lab rotator V1.00. 
(ii) Stain-free gel preparation 
(a) TGX Stain-Free polyacrylamide gels (7.5%, 10% & 12 %) obtained from Bio-Rad, were 
prepared by adding the two pre-mixed solutions (for the running and stacking gel 
respectively) to each other according to the manufacturer’s instructions. 
(b) Alternatively, stain-free polyacrylamide gels were prepared as described in the Chapter 2, 
Section 8.2(i), however 50 µl 2,2-Trichloroethanol purchased from Sigma-Aldrich (St Louis, 
MO), was added to the mixture and 50 µl less water, creating a stain-free gel.   
When the gels were set after 40 min, the same sample loading and running procedure as 
described in Chapter 2, Section 8.2(i) was followed. After the proteins were separated in the 
polyacrylamide gels, the gels were activated using the Bio-Rad ChemiDoc™ MP System. 
During the activation time, one can visualize whether the proteins separated equally on the 
gels. The stain-free polyacrylamide gels were also transferred to PVDF membranes. Once 
the transfer period was finished, the membranes were scanned to ensure that the proteins 
did transfer from the gels to the membranes. Scanning was carried out using the Bio-Rad 
ChemiDoc™ MP System. 
The information of the amount of transferred proteins per lane was stored on the Bio-Rad 
ChemiDoc™ MP System for normalization purposes. 
 
(iii) Precast gels 
Bio-Rad Mini-PROTEAN® TGX Stain-Free™ Precast gradient gels purchased from Bio-Rad 
were used for the determination of Total (T)-ATM, Phospho (P)-ATM, T-IRS1 and P-IRS1.  
The same sample loading protocol was followed as described in Chapter 2, Section 8.2; 
however a specific HiMark™ Pre-Stained Protein ladder purchased at Novex®, Thermo 
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Scientific was loaded in the first well. The HiMark™ ladder range between 30-460 kDa and is 
therefore specifically designed for proteins with high molecular weights.  
After loading the samples, the gel compartment tank was once again filled with running 
buffer. To compensate for the big ATM (370 kDa) and IRS1 (180 kDa) proteins, the stain-free 
precast gels were subjected for 90 min to SDS-PAGE at 200V, 200mA. After the proteins 
were separated on the stain-free precast gels, the gels were activated using the Bio-Rad 
ChemiDoc™ MP System to visualize whether the proteins separated equally on the gels.  
Proteins on the stain-free precast gels were transferred to PVDF membranes for 90 min at 
200V, 200mA. The transfer buffer, containing half the amount of methanol than previously 
described, was specially prepared for optimal transfer of the big ATM and IRS1 proteins. 
After the transfer period, the membranes were scanned to ensure that the proteins did 
transfer from the gels to the membranes. Scanning was once again carried out using the Bio-
Rad ChemiDoc™ MP System and the data was stored on the system for normalization 
purposes. 
8.3. Immunodetection of protein 
The membranes where incubated for 2 hours at room temperature in 50 ml 5% milk (5 g fat 
free milk powder purchased from Elite, dissolved in 100 ml TBS-Tween solution). This step 
was to ensure non-specific site blocking. When the blocking period was finished, the 
membranes were washed with the TBS-Tween solution for 30 min (3 x 10 min) on the lab 
rotator V1.00. These membranes were individually subjected to primary antibodies directed 
against: T-IRS1 and P-IRS1 (Ser307), T-PI3K and P-PI3K p85 (Tyr458)/p55 (Tyr199), T-
PTEN and P-PTEN (Ser380/Thr382/Tyr383), T-ATM and P-ATM (Ser1981), T-PKB and P-
PKB (Ser473),  T-AS160 and P-AS160 (Thr642), T-GSK-3β and P- GSK-3β (Ser9), T-AMPK 
and P-AMPK (Thr172), and GLUT4 respectively where after it was left to incubate at 4  C 
overnight. The antibodies were diluted in TBS-Tween or in primary SignalBoost™ 
Immunoreaction Enhancer. SignalBoost™ was used to enhance the signal of certain 
antibodies e.g. IRS1, ATM and GLUT4. 
All the antibodies were rabbit monoclonal antibodies, except for GLUT4 which was a mouse 
monoclonal antibody.  
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Table 2.4: Western Blot analysis 
 
 
 
 
 
 
 
 
 
 
 
After incubation, the membranes were washed in TBS-Tween solution for 30 min (3 x 10 
min) on the lab rotator V1.00. An Anti-rabbit immunoglobulin G, HRP- conjugated secondary 
antibody (from donkey), purchased from Cell Signaling Technology, Inc, was diluted 
according to Table 2.4 for all the antibodies except GLUT4. The GLUT4 incubated 
membranes were probed in diluted Anti-mouse immunoglobulin G, HRP- conjugated 
secondary antibody also purchased from Cell Signaling Technology, Inc. The secondary 
antibody for ATM was diluted in secondary SignalBoost™ Immunoreaction Enhancer to 
enhance the secondary signal.   
Membranes were immersed in these diluted secondary antibodies for 1 hour. During this 
time, the secondary antibody bound to the primary antibody to eventually initiate the signal. 
The membranes were washed again in TBS-Tween solution for 30 min (3 x 10 min) on the 
lab rotator V1.00 to remove the excess secondary antibody. 
To visualize the proteins of interest on the membranes, Clarity™ enhanced 
chemiluminescence (ECL), purchased from Bio-Rad, was added to each membrane and left 
to incubate for 5 min.  
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Following this, the membranes were exposed either (i) in the Dark Room or (ii) using the Bio-
Rad ChemiDoc™ MP System.  
(i) Dark Room 
The ATM and IRS1 membranes were exposed to an autoradiography film (Amersham™ 
Hyperfilm™ ECL). During the exposure time, the HRP (secondary antibody) reacts with the 
specific detection reagent in the ECL which results in a light emission. This signal is captured 
on the radiography film which is then developed and fixed. After thorough washing with 
water, the radiography films were allowed to dry where after they were laser-scanned for 
densitometry. Once scanned the band intensities were quantified using the program UN-
SCAN-IT TM (version 5.1, Silkscience) image analysis. 
(ii)  Bio-Rad ChemiDoc™ MP System 
The stain-free membranes were exposed in the Bio-Rad ChemiDoc™ MP System. The 
exposure time as well as the number of images one would like to take was set beforehand 
and visualised throughout the procedure. If the bands were coloured red, the blot was 
overexposed and not used for analysis purposes. The best images were saved for 
normalisation of the density of the individual bands against the total amount of protein per 
lane transferred to the PVDF membrane that was previously stored. 
  
8.4.  Stripping of the membranes 
 
All the total probed membranes were stripped and re-probed/reblotted with the specific 
phospho antibodies. The stripping procedure included: incubation of the membranes 2 x 5 
min in dH2O, 1 x 5 min in 0.2 M NaOH and again 2 x 5 min in distilled water. After stripping, 
the membranes were blocked in 5% milk, and the same procedures as described in Chapter 
2, Section 8.3 followed.  
 
9. Statistical analysis 
All the data were statistically analysed using GraphPad Prism 5. All values were expressed as 
Mean ± Standard Error of the Mean (SEM). One-way Analysis of Variance (ANOVA), followed by 
a Bonferroni post-hoc test was performed to determine the differences in response to different 
treatments on both the control and HFD animals. A Two-way ANOVA with repeated measures 
was performed to determine significant differences obtained for the OGTT analysis. 
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Furthermore, a Two-way ANOVA was performed on P-ATM, P-PI3K and P-PKB from both the 
control and HFD animals to specifically determine the effect of KU 60019 on baseline P-PI3K 
levels and insulin stimulated phosphorylation of ATM and PKB. A p-value of ˂ 0.05 was 
regarded as significant. 
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CHAPTER 3: RESULTS 
Over a period of 16 weeks, half of the animals received a HFD (containing 40% fat) to induce 
insulin resistance compared to group two, the age-matched controls. Using both these animal 
models, the relationship between ATM and insulin signalling/ insulin resistance was investigated.  
1. Biometric data:  
1.1.  Body weight, IP fat weight, Fasting blood glucose levels, Insulin and HOMA IR 
index 
Table 3.1: Biometric data 
 
HOMA IR index; n = 25 per group for the Body weight and IP fat weight; n = 10 for Fasting 
blood glucose levels; n = 6 for control Insulin and HOMA IR index levels, n = 5 for HFD 
insulin and HOMA IR index levels. The data are expressed as Mean ± SEM (* p < 0.05; *** p 
< 0.001 HFD vs. control). 
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1.2. Body Weight 
The Body weight of the control (430.66 ± 15.48 g) and HFD (462.84 ± 10.32 g) animals 
showed no significant differences. Therefore, consumption of the HFD did not increase the 
overall body weight gain of these animals; n = 25 per group (Table 3.1; Figure 3.1).  
 
 
 
 
 
 
 
 
Figure 3.1: Body weight (g) of the control vs. the HFD animals measured after 16 weeks 
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1.3. IP fat weight 
After 16 weeks, the HFD animals gained significantly more IP fat than the control animals 
(33.68 ± 2.42 g vs. 19.06 ± 1.51 g; p < 0.001 (HFD vs. control); n = 25 per group (Table 3.1; 
Figure 3.2).  
 
 
 
 
 
 
 
 
Figure 3.2: IP fat weight (g) of the control vs. the HFD animals measured after 16 weeks 
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1.4. OGTT 
In week 15, a group of animals was fasted overnight to determine their glucose tolerance by 
performing an OGTT. The baseline glucose levels (0 min) of the control and HFD animals 
differed significantly (4.72 ± 0.05 vs. 5.72 ± 0.16 mmol/L; p < 0.001) (Table 3.2, Figure 3.3). 
When 1g/kg sucrose was orally administered to the animals, the HFD animals presented with 
significantly higher glucose levels from 3 min to 45 min when compared to the control 
animals. There were no significant differences between the groups at 60 min and 90 min 
respectively; however after 120 min the HFD animals once again displayed a significantly 
higher blood glucose concentration when compared to the control animals (4.67 ± 0.19 vs. 
5.44 ± 0.20; p < 0.05); n = 9 for the control group, n = 5 for the HFD  group.  
Table 3.2: OGTT (mmol/L plasma glucose) values in the control and HFD animals 
 
 
 
 
 
 
 
 
 
OGTT data is expressed as Mean ± SEM. n = 9 for the control animals; n = 5 for the HFD 
animals (* p < 0.05; ** p < 0.01; *** p < 0.001 HFD vs. control). A Two-way ANOVA with 
repeated measures was performed to determine significant differences. 
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Figure 3.3: OGTT (mmol/L plasma glucose) of control and HFD animals measured in week 
15 at 3 min, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 45 min, 60 min and 120 min 
respectively, after the administration 1g/kg sucrose 
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1.5. Basal blood glucose levels 
After 16 weeks on the respective diets, the basal blood glucose levels of the HFD group (5.4 
± 0.15 mmol/L; n =10) was significantly increased when compared to the control group (4.71 
± 0.05 mmol/L; n = 10); p = 0.0004 (HFD vs. control) (Table 3.1; Figure 3.4).  
 
 
 
 
 
 
 
 
Figure 3.4: Basal glucose levels (mmol/L) of fasting control vs. HFD animals measured after 
16 weeks 
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1.6. Insulin levels 
The fasting insulin levels of the HFD group was significantly elevated when compared to the 
control group; p= 0.03 (HFD vs. control). The HFD animals (n = 5) displayed insulin levels of 
14.58 ± 2.03 mIU/ml, whereas the control group (n = 6) presented with lower insulin levels of 
6.68 ± 2.21 mIU/ml (Table 3.1; Figure 3.5). 
 
 
 
 
 
 
 
 
Figure 3.5: Insulin levels (mIU/ml) of the control vs. the HFD animals measured after 16 
weeks 
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1.7. HOMA IR index 
The HOMA IR index of the HFD group (4.68 ± 0.87; n = 5) was significantly higher when 
compared to the control group (1.55 ± 0.70, n = 6); p = 0.0188 (HFD vs. control) (Table 3.1; 
Figure 3.6). 
 
 
 
 
 
 
 
 
Figure 3.6: HOMA IR index values of the control vs. the HFD animals after 16 weeks 
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2DG uptake with Chloroquine as activator 
2. 2DG uptake 
 
2.1. 2DG uptake levels (pmol 2DG/mg protein/30min) in cardiomyocytes from young 
control animals in response to Chloroquine stimulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7(a): 2DG uptake levels (pmol 2DG/mg protein/30min) in response to treatment 
with 5 µM, 3 µM and 1 µM Cholorquine 
   
 
As Choloroquine did not initiate 2DG uptake, it was not further used in the study as an 
activator. 
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2.2. 2DG uptake levels (pmol 2DG/mg protein/30min) in the cardiomyocytes from 
control, age-matched control and HFD animals in response to insulin stimulation 
(1 nM, 10 nM, 100 nM) 
Cardiomyocytes from the age-matched control animals presented with significantly lower 
basal 2DG uptake levels and also in response to INS 10 and INS 100 stimulation when 
compared to cardiomyocytes from the young control animals (n = 3-11 biological replicates 
per group analysed in duplicate; #, ##, ###, p < 0.01 to the respective column with similar 
sign) (Figure 3.7(b)). Stimulation with INS 10 and INS 100 respectively increased 2DG 
uptake in cardiomyocytes from young control animals when compared to cardiomyocytes 
from baseline young control values, n = 3-11 biological replicates per group analysed in 
duplicate; p < 0.01. Furthermore, in cardiomyocytes from the age-matched controls INS 10 
and INS 100 also significantly increased 2DG uptake when compared to baseline 
cardiomyocyte age-matched values, n = 5 biological replicates per group analysed in 
duplicate; p < 0.05 and p < 0.01 respectively. In the HFD animals INS 10 and INS 100 
significantly increased 2DG uptake in the cardiomyocytes when compared to baseline HFD 
values; n = 3-5 biological replicates per group analysed in duplicate; p < 0.05. No differences 
were observed between the cardiomyocytes from age-matched control and HFD animals. 
 
 
 
 
 
 
 
 
Figure 3.7(b): 2DG uptake levels (pmol 2DG/mg protein/30min) in response to the 
respective stimulation with 1 nM, 10 nM and 100 nM insulin in young control, age-matched 
control and HFD cardiomyocytes 
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2.3. 2DG uptake levels (pmol 2DG/mg protein/30min) measured in the cardiomyocytes 
from control and HFD animals in response to treatment with activator (INS 10) and 
inhibitors (WM & KU 60019). 
The 2DG uptake in the cardiomyocytes from control animals were significantly elevated in 
response to INS 10 stimulation when compared to baseline control values (n = 3-7 biological 
replicates per group analysed in duplicate; p < 0.05). When the control cardiomyocytes were 
further treated with both WM and KU 60019 in combination with INS 10, the 2DG uptake 
levels significantly decreased for both conditions (p < 0.05 and p < 0.01 respectively) when 
compared to INS 10 (Figure 3.8). 
HFD cardiomyocytes stimulated with INS 10, presented with significantly higher 2DG uptake 
levels when compared to the baseline HFD values (n= 3-5 biological replicates per group 
analysed in duplicate; p < 0.001). Furthermore, after treatment with WM in combination with 
INS 10, 2DG uptake was significantly decreased when compared to HFD INS 10; p < 0.001.  
Treatment with the ATM inhibitor, KU 60019 in combination with INS 10 also significantly 
lowered 2DG uptake when compared to HFD INS 10; p < 0.05) (Figure 3.8). No differences 
were observed between cardiomyocytes from the control and HFD animals. 
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Figure 3.8: 2DG uptake values for cardiomyocytes from control and HFD animals treated 
respectively with the specific activator (INS 10 nM) and inhibitors (WM and KU 60019) 
 
3. Western Blot data 
Western Blotting was performed on cardiomyocytes from both the age-matched control and HFD 
animas manipulated with the activator, INS 10; the PI3K inhibitor, WM; and the ATM inhibitor, 
KU 60019, to measure the expression and activation of important insulin signalling intermediates 
such as IRS1, PI3K, PTEN, PKB, AS160, GSK-3β, AMPK and GLUT4. The expression and 
phosphorylation of ATM was also determined in cardiomyocytes from both animal models 
treated under the same conditions, to identify the postulated relationship between ATM and 
insulin signalling. 
In the following Sections, the total expression (a & b), phosphorylation (c & d) and the P:T Ratio 
(e & f) will be presented as graphs for cardiomyocytes from both the age-matched control and 
HFD animals. 
Stellenbosch University  https://scholar.sun.ac.za
61 
 
T-IRS1 Control
C
O
N
TR
O
L
IN
S
 1
0
W
M
W
M
 &
 IN
S
 1
0
 K
U
 6
00
19
K
U
 6
00
19
 &
 IN
S
 1
0
0.0
0.5
1.0
1.5
2.0
n = 2 biological replicates per
group analysed in duplicate
+ C = 7-8 w eek old untreated control
Groups
A
rb
it
ra
ry
 D
e
n
s
it
o
m
e
tr
y
 u
n
it
s
The total- and phospho-protein graphs of the HFD animals are presented as a ratio to the age-
matched control loaded on that same gel. Consequently the HFD animals could be compared to 
the control animals.  
The positive control (+C), a 7-8 week untreated control, was loaded in to the first well of each 
blot for normalization purposes only. 
3.1. IRS1 
a) Total (T) expression control 
 
 No significant differences were observed in the T-IRS1 expression in the 
cardiomyocytes from control animals; n = 2 biological replicates per group analysed in 
duplicate (Figure 3.9). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: T-IRS1 expression (Arbitrary Densitometry units) in the cardiomyocytes from 
control animals 
 
180 kDa 
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b) Total (T) expression HFD 
In response to the inhibition with WM, T-IRS1 expression in the cardiomyocytes from 
HFD animals were downregulated when compared to the baseline HFD animals; n = 1 
biological replicate per group analysed in duplicate; p < 0.05 (WM vs. HFD control) 
(Figure 3.10). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: T-IRS1 expressed as a HFD: Control Ratio 
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c) Phosphorylated (P) levels control 
In the cardiomyocytes from control animals, no significant differences were observed in 
the phosphorylation of IRS1; n = 2 biological replicates per group analysed in duplicate 
(Figure 3.11).   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: P-IRS1 levels (Arbitrary Densitometry units) in the cardiomyocytes from 
control animals 
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d) Phosphorylated (P) levels HFD 
The cardiomyocytes from HFD animals showed significantly increased basal 
phosphorylation of IRS1 at Ser307 when compared to the cardiomyocytes from control 
animals; n = 1 biological replicate per group analysed in duplicate; p < 0.05 (HFD control 
vs. control). Furthermore, the cardiomyocytes from HFD animals treated with WM and 
KU 60019 respectively, and in combination with INS 10, presented with significantly 
decreased phosphorylation of IRS1 when compared to the baseline HFD group and the 
INS 10 group respectively; p < 0.05 (KU 60019 or WM vs. HFD control; KU 60019 & INS 
10 or WM & INS 10 vs. INS 10)  (Figure 3.12). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: P-IRS1 levels expressed as a HFD: Control Ratio 
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e) P:T Ratio control 
The Ratio of phosphorylated vs. total IRS1 showed no significant differences in the 
cardiomyocytes from the control untreated and treated animals; n = 2 biological 
replicates per group analysed in duplicate (Figure 3.13). 
 
 
 
 
 
 
 
 
Figure 3.13: Ratio of phosphorylated vs. total levels of IRS1 in the cardiomyocytes from 
control animals 
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f) P:T Ratio HFD 
The Ratio of phosphorylated vs. total IRS1 in cardiomyocytes from the baseline HFD 
animals significantly increase when treated with WM; n = 1 biological replicate per group 
analysed in duplicate; p < 0.05 (WM vs. HFD control) (Figure 3.14).   
 
 
 
 
 
 
 
 
Figure 3.14: Ratio of phosphorylated vs. total levels of IRS1 in the cardiomyocytes from 
HFD animals 
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3.2. PI3K 
a) Total (T) expression control 
 
No significant differences were observed in the total expression of PI3K in the 
cardiomyocytes from control animals; n = 4-6 biological replicates per group analysed in 
duplicate (Figure 3.15). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: T-PI3K expression (Arbitrary Densitometry units) in the cardiomyocytes 
from control animals 
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b) Total (T) expression HFD 
 
T-PI3K expression in the cardiomyocytes from HFD animals were significantly 
downregulated at baseline when compared to the cardiomyocytes from control animals; n 
= 3-5 biological replicates per group analysed in duplicate; p < 0.01 (HFD control vs. 
control) (Figure 3.16).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: T-PI3K expressed as a HFD: Control Ratio 
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c) Phosphorylated (P) levels control 
 
The phosphorylation of PI3K significantly decreased in the cardiomyocytes from control 
animals when treated with KU 60019; n = 4-6 biological replicates per group analysed in 
duplicate; p < 0.01 (KU 60019 vs. control) (Figure 3.17). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: P-PI3K levels (Arbitrary Densitometry units) in the cardiomyocytes from 
control animals 
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d) Phosphorylated (P) levels HFD 
 
No significant differences were observed between the phosphorylation of PI3K in the 
cardiomyocytes from control and HFD animals at baseline. Furthermore, there were also 
no differences in phosphorylation of PI3K in the cardiomyocytes from different HFD 
treated groups; n = 3-5 biological replicates per group analysed in duplicate (Figure 
3.18).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: P-PI3K levels expressed as a HFD: Control Ratio 
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KU 60019 on P-PI3K
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Two-way ANOVA to illustrate the effect of KU 60019 on P-PI3K in cardiomyocytes 
from both the control and HFD animals 
The effect of KU 60019 on P-PI3K was significant in cardiomyocytes from both animal 
groups, n = 3-6 biological replicates per group analysed in duplicate; p < 0.05 (KU 60019 
vs. control; KU 60019 vs. HFD control) (Figure 3.19).  
 
 
 
 
 
 
 
 
Figure 3.19: The effect of KU 60019 on P-PI3K  
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e) P:T Ratio control 
 
No significant differences in the PI3K P:T Ratio were observed; n = 4-6 biological 
replicates per group analysed in duplicate (Figure 3.20).  
 
 
 
 
 
 
 
 
Figure 3.20: Ratio of phosphorylated vs. total levels of PI3K in the cardiomyocytes from 
control animals 
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f) P:T Ratio HFD 
 
No significant differences in the PI3K P:T Ratio were observed in the cardiomyocytes 
from HFD animals; n = 3-5 biological replicates per group analysed in duplicate (Figure 
3.21).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21: Ratio of phosphorylated vs. total levels of PI3K in the cardiomyocytes from 
HFD animals 
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3.3. PTEN 
a) Total (T) expression control 
 
No significant differences in the total expression of PTEN was observed between the 
cardiomyocytes from different control treated animals; n = 4 biological replicates per 
group analysed in duplicate (Figure 3.22).  
  
 
 
 
 
 
 
 
 
 
 
Figure 3.22: T-PTEN expression (Arbitrary Densitometry units) in the cardiomyocytes 
from control animals 
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b) Total (T) expression HFD 
 
The total expression of PTEN in the cardiomyocytes from HFD animals did not differ from 
the cardiomyocytes from control animals at baseline. Furthermore, when the 
cardiomyocytes from different HFD treatment groups were analysed, no significant 
differences were observed in the total expression of PTEN; n = 3 biological replicates per 
group analysed in duplicate (Figure 3.23).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23: T-PTEN expressed as a HFD: Control Ratio 
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c) Phosphorylated (P) levels control 
 
Cardiomyocytes from the control animals showed no significant differences in the 
phosphorylation of PTEN; n = 4 biological replicates per group analysed in duplicate 
(Figure 3.24).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24: P-PTEN levels (Arbitrary Densitometry units) in the cardiomyocytes from 
control animals 
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d) Phosphorylated (P) levels HFD 
 
No significant differences were observed between the phosphorylation of PTEN in the 
cardiomyocytes from HFD and control animals at baseline. Also, no significant 
differences in PTEN phosphorylation were observed among the cardiomyocytes from 
different HFD treated animals; n = 2-3 biological replicates per group analysed in 
duplicate (Figure 3.25).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25: P-PTEN levels expressed as a HFD: Control Ratio 
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e) P:T Ratio control 
 
No significant differences in the PTEN P:T Ratio were observed; n = 4 biological 
replicates per group analysed in duplicate (Figure 3.26).  
 
 
 
 
 
 
 
 
Figure 3.26: Ratio of phosphorylated vs. total levels of PTEN in the cardiomyocytes from 
control animals 
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f) P:T Ratio HFD 
 
No significance was observed in the PTEN P:T Ratio in the cardiomyocytes from HFD 
animals (Figure 3.27). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27: Ratio of phosphorylated vs. total levels of PTEN in the cardiomyocytes from 
HFD animals 
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3.4. ATM 
a) Total (T) expression control 
In the cardiomyocytes from control animals, the expression of T-ATM was significantly 
downregulated when the INS 10 group and the INS 10 in combination with KU 60019 
group were compared; n = 4-8 biological replicates per group analysed in duplicate; p < 
0.001 (KU 60019 & INS 10 vs. INS 10) (Figure 3.28). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28: T-ATM expression (Arbitrary Densitometry units) in the cardiomyocytes 
from control animals 
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b) Total (T) expression HFD 
The total expression of ATM was significantly downregulated in the cardiomyocytes from 
HFD animals when compared to the control animals at baseline; n = 4-9 biological 
replicates per group analysed in duplicate; p < 0.001 (HFD control vs. control) (Figure 
3.29). Furthermore, the KU 60019 in combination with INS 10 group, significantly lowered 
the total expression of ATM when compared to the INS 10 group; p < 0.05 (KU 60019 & 
INS 10 vs. INS 10).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.29: T-ATM expressed as a HFD: Control Ratio 
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c) Phosphorylated (P) levels control 
The cardiomyocytes from control animals showed no significant differences in the 
phosphorylation of ATM after the different manipulations; n = 4-6 biological replicates per 
group analysed in duplicate (Figure 3.30).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.30: P-ATM levels (Arbitrary Densitometry units) in the cardiomyocytes from 
control animals 
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d) Phosphorylated (P) levels HFD 
The phosphorylation of ATM was significantly decreased in the cardiomyocytes from 
HFD animals when compared to the cardiomyocytes from control animals at baseline; n 
= 4-6 biological replicates per group analysed in duplicate; p < 0.05 (HFD control vs. 
control) (Figure 3.31). The KU 60019 & INS 10 group significantly decreased the 
phosphorylation of ATM when compared to the INS 10 treated group; p < 0.05 (KU 
60019 & INS 10 vs. INS 10). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.31: P-ATM levels expressed as a HFD: Control Ratio  
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KU 60019 on P-ATM
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Two-way ANOVA to illustrate the effect of KU 60019 on insulin-stimulated P-ATM in 
cardiomyocytes from both the control and HFD animals 
The effect of KU 60019 on P-ATM was significant in cardiomyocytes from both animal 
models, n = 5-6 biological replicates per group analysed in duplicate; p=0.02 (KU 60019 
& INS 10 vs. control & INS 10; KU 60019 & INS 10 vs. HFD & INS 10) (Figure 3.32).  
 
 
 
 
 
 
 
 
Figure 3.32: Effect of KU 60019 on insulin-stimulated P-ATM  
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e) P:T Ratio control 
According to the P:T Ratio of the cardiomyocytes from control animals, the KU 60019 
group significantly upregulated the phosphorylation of ATM when compared to the 
baseline values; n = 3-5 biological replicates per group analysed in duplicate; p < 0.01 
(KU 60019 vs. control) (Figure 3.33). 
 
 
 
 
 
 
 
 
Figure 3.33: Ratio of phosphorylated vs. total levels of ATM in the cardiomyocytes from 
control animals 
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f) P:T Ratio HFD 
The ATM P:T Ratio of the INS 10 group was significantly decreased when compared to 
the cardiomyocytes from baseline HFD  animals; n = 3-6 biological replicates per group 
analysed in duplicate; p < 0.05 (INS 10 vs. HFD control) (Figure 3.34). In addition the KU 
60019 treated group also significantly decreased the phosphorylation of ATM when 
compared to the cardiomyocytes from baseline HFD animals; p < 0.01 (KU 60019 vs. 
HFD control).   
 
 
 
 
 
 
 
 
Figure 3.34: Ratio of phosphorylated vs. total levels of ATM in the cardiomyocytes from 
HFD animals 
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3.5. PKB 
a) Total (T) expression control 
No significant differences were observed in the total expression of PKB in the 
cardiomyocytes from control animals; n = 4-10 biological replicates per group analysed in 
duplicate (Figure 3.35). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.35: T-PKB expression (Arbitrary Densitometry units) in the cardiomyocytes from 
control animals 
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b) Total (T) expression HFD 
The total expression of PKB was downregulated in the cardiomyocytes from HFD 
animals when compared to the cardiomyocytes from control animals at baseline; n = 4-9 
biological replicates per group analysed in duplicate; p < 0.01 (HFD control vs. control) 
(Figure 3.36).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.36: T-PKB expressed as a HFD: Control Ratio 
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c) Phosphorylated (P) levels control 
No significant differences were observed in the phosphorylation of PKB in the 
cardiomyocytes from control treated groups; n = 4-7 biological replicates per group 
analysed in duplicate (Figure 3.37). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.37: P-PKB levels (Arbitrary Densitometry units) in the cardiomyocytes from 
control animals 
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d) Phosphorylated (P) levels HFD 
No significant differences were observed between PKB phosphorylation in the 
cardiomyocytes from control and HFD animals at baseline; n = 4-7 biological replicates 
per group analysed in duplicate (Figure 3.38). There was also no significant differences 
in P-PKB among the cardiomyocytes from HFD treated groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38: P-PKB levels expressed as a HFD: Control Ratio  
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KU 60019 on P-PKB
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0.0
0.5
1.0
1.5
2.0
Minus KU 60019
Plus KU 60019
Effect of KU 60019: P=0.001
*
CONTROL &
INS 10
HFD &
INS 10
n = 3-4 biological replicates per
group analysed in duplicate
* p < 0.05
A
rb
it
ra
ry
 D
e
n
s
it
o
m
e
tr
y
 u
n
it
s
Two-way ANOVA to illustrate the effect of KU 60019 on insulin-stimulated P-PKB in 
cardiomyocytes from both the control and HFD animals 
Cardiomyocytes from the control animals, treated with KU 60019 significantly 
downregulated P-PKB when compared to INS 10; n = 3-4 biological replicates per group 
analysed in duplicate; p < 0.05 (KU 60019 & INS 10 vs. control & INS 10). The overall 
effect of KU 60019 was significant on cardiomyocytes from both groups; p=0.001 (KU 
60019 & INS 10 vs. control & INS 10; KU 60019 & INS 10 vs. HFD & INS 10) (Figure 
3.39). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.39: Effect of KU 60019 on insulin-stimulated P-PKB  
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e) P:T Ratio control 
The cardiomyocytes from control animals presented with no significant differences in the 
PKB P:T Ratio; n = 4-7 biological replicates per group analysed in duplicate (Figure 
3.40). 
 
 
 
 
 
 
 
 
Figure 3.40: Ratio of phosphorylated vs. total levels of PKB in the cardiomyocytes from 
control animals 
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f) P:T Ratio HFD 
No significant differences in the cardiomyocytes from HFD animals were observed in the 
PKB P:T Ratio; n = 4-7 biological replicates per group analysed in duplicate (Figure 
3.41). 
 
 
 
 
 
 
 
 
Figure 3.41: Ratio of phosphorylated vs. total levels of PKB in the cardiomyocytes from 
HFD animals 
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3.6. AS160 
a) Total (T) expression control 
No significant differences were observed in the total expression of AS160 in the 
cardiomyocytes from control animals; n = 3 biological replicates per group analysed in 
duplicate (Figure 3.42). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.42: T-AS160 expression (Arbitrary Densitometry units) in the cardiomyocytes 
from control animals 
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b) Total (T) expression HFD 
 
No significant differences were observed in the total expression of AS160 in the 
cardiomyocytes from HFD vs. the control animals; n = 3 biological replicates per group 
analysed in duplicate (Figure 3.43). There were also no significant differences in T-
AS160 expression among the cardiomyocytes from HFD treated animals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.43: T-AS160 expressed as a HFD: Control Ratio 
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c) Phosphorylated (P) levels control 
 
In the cardiomyocytes from control animals, treatment with WM decreased the basal 
phosphorylation levels of AS160; n = 3 biological replicates per group analysed in 
duplicate; p < 0.001 (WM vs. control) (Figure 3.44). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.44: P-AS160 levels (Arbitrary Densitometry units) in the cardiomyocytes from 
control animals 
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d) Phosphorylated (P) levels HFD 
Phosphorylation of AS160 in the cardiomyocytes from HFD animals were significantly 
lower at baseline when compared to the cardiomyocytes from control animals; n = 3 
biological replicates per group analysed in duplicate; p < 0.001 (HFD control vs. control) 
(Figure 3.45). In contrast to the cardiomyocytes from control animals, cells from HFD 
animals stimulated with INS 10 resulted in significantly upregulated phosphorylation of 
AS160; p < 0.01 (INS 10 vs. HFD control). Furthermore, WM but not KU 60019, inhibited 
this stimulation; p < 0.05 (WM & INS 10 vs. INS 10).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.45: P-AS160 levels expressed as a HFD: Control Ratio  
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e) P:T Ratio control 
The AS160 P:T Ratio significantly decreased in the cardiomyocytes from control animals 
treated with WM when compared to the baseline values; n = 3 biological replicates per 
group analysed in duplicate; p < 0.01 (WM vs. control) (Figure 3.46). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.46: Ratio of phosphorylated vs. total levels of AS160 in the cardiomyocytes 
from control animals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ratio of phosphorylated versus total AS160
(Control)
C
O
N
TR
O
L
IN
S
 1
0
W
M
W
M
 &
 IN
S
 1
0
 K
U
 6
00
19
K
U
 6
00
19
 &
 IN
S
 1
0
0
1
2
3
   n = 3 biological replicates per
   group analysed in duplicate.
** p < 0.01
**
Groups
R
a
ti
o
 p
h
o
s
p
h
o
:t
o
ta
l
Stellenbosch University  https://scholar.sun.ac.za
99 
 
Ratio of phosphorylated versus total AS160
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f) P:T Ratio HFD 
 
The AS160 P:T Ratio significantly increased in the cardiomyocytes from HFD animals in 
response to INS 10 stimulation when compared to the cardiomyocytes from baseline 
HFD animals; n = 3 biological replicates per group analysed in duplicate; p < 0.01 (INS 
10 vs. HFD control) (Figure 3.47). 
 
 
 
 
 
 
 
 
 
Figure 3.47: Ratio of phosphorylated vs. total levels of AS160 in the cardiomyocytes 
from HFD animals 
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3.7. GSK-3β 
a) Total (T) expression control 
 
Cardiomyocytes from control animals treated with KU 60019 & INS 10 showed a 
significant increase in the total expression of GSK-3β when compared to the 
cardiomyocytes from control animals treated with only INS 10; n = 4-5 biological 
replicates per group analysed in duplicate; p < 0.05 (KU 60019 & INS 10 vs. INS 10) 
(Figure 3.48). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.48: T-GSK-3β expression (Arbitrary Densitometry units) in the cardiomyocytes 
from control animals 
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b) Total (T) expression HFD 
The total expression of GSK-3β was significantly downregulated in the cardiomyocytes 
from HFD animals when compared to the cardiomyocytes from control animals at 
baseline; n = 3-4 biological replicates per group analysed in duplicate; p < 0.01 (HFD 
control vs. control) (Figure 3.49). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.49: T-GSK-3β expressed as a HFD: Control Ratio 
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c) Phosphorylated (P) levels control 
No significant differences were observed in the phosphorylation of GSK-3β in the 
cardiomyocytes from control animals, n = 4-5 biological replicates per group analysed in 
duplicate (Figure 3.50). 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.50: P-GSK-3β levels (Arbitrary Densitometry units) in the cardiomyocytes from 
control animals 
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d) Phosphorylated (P) levels HFD 
The cardiomyocytes from HFD control animals presented with a significantly lower GSK-
3β phosphorylation than the cardiomyocytes from control animals at baseline; n = 3-4 
biological replicates per group analysed in duplicate; p < 0.05 (HFD control vs. control) 
(Figure 3.51).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.51: P-GSK-3β levels expressed as a HFD: Control Ratio 
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e) P:T Ratio control 
No significant differences were observed in the GSK-3β P:T Ratio in the cardiomyocytes 
from control animals; n = 4-5 biological replicates per group analysed in duplicate (Figure 
3.52). 
 
 
 
 
 
 
 
 
Figure 3.52: Ratio of phosphorylated vs. total levels of GSK-3β in the cardiomyocytes 
from control animals 
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f) P:T Ratio HFD 
 
Stimulation with INS 10 in the cardiomyocytes from HFD animals significantly increased 
the P:T Ratio of GSK-3β when compared to cardiomyocytes from baseline HFD values; n 
= 3-4 biological replicates per group analysed in duplicate; p < 0.05 (INS 10 vs. HFD 
control) (Figure 3.53). 
 
 
 
 
 
 
 
 
Figure 3.53: Ratio of phosphorylated vs. total levels of GSK-3β in the cardiomyocytes 
from HFD animals 
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3.8. AMPK 
a) Total (T) expression control 
Cardiomyocytes from control animals treated with WM showed a significant increase in 
the total expression of AMPK when compared to the cardiomyocytes from baseline 
values; n = 4-6 biological replicates per group analysed in duplicate; p < 0.05 (WM vs. 
control) (Figure 3.54). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.54: T-AMPK expression (Arbitrary Densitometry units) in the cardiomyocytes 
from control animals 
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b) Total (T) expression HFD 
The cardiomyocytes from HFD animals at baseline presented with significantly lower T-
AMPK expression when compared to the cardiomyocytes from control animals; n = 3-5 
biological replicates per group analysed in duplicate; p < 0.05 (HFD control vs. control) 
(Figure 3.55). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.55: T-AMPK expressed as a HFD: Control Ratio 
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c) Phosphorylated (P) levels control 
No significant differences were observed in the phosphorylation of AMPK in the 
cardiomyocytes from control animals with any of the interventions; n = 4-6 biological 
replicates per group analysed in duplicate (Figure 3.56). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.56: P-AMPK levels (Arbitrary Densitometry units) in the cardiomyocytes from 
control animals 
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d) Phosphorylated (P) levels HFD 
The phosphorylation of AMPK was significantly downregulated in the cardiomyocytes 
from HFD animals at baseline when compared to the cardiomyocytes from control 
animals; n = 3-5 biological replicates per group analysed in duplicate; p < 0.001 (HFD 
control vs. control) (Figure 3.57). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.57: P-AMPK levels expressed as a HFD: Control Ratio 
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e) P:T Ratio control 
 
No significant differences were observed in the AMPK P:T Ratio in the cardiomyocytes 
from control animals; n = 4-6 biological replicates per group analysed in duplicate (Figure 
3.58). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.58: Ratio of phosphorylated vs. total levels of AMPK in the cardiomyocytes from 
control animals 
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f) P:T Ratio HFD 
 
No significant differences were observed in the AMPK P:T Ratio in the cardiomyocytes 
from HFD animals; n = 3-5 biological replicates per group analysed in duplicate (Figure 
3.59). 
 
 
 
 
 
 
 
 
Figure 3.59: Ratio of phosphorylated vs. total levels of AMPK in the cardiomyocytes from 
HFD animals 
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3.9. GLUT4 
a) Total (T) expression control 
The expression of GLUT4 in cardiomyocytes from the control animals respectively 
increased significantly in response to INS 10 and WM stimulation when compared to the 
cardiomyocytes from baseline values; n = 3 biological replicates per group analysed in 
duplicate, p < 0.05 (INS 10 vs. control; WM vs. control) (Figure 3.60)  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.60: GLUT4 expression (Arbitrary Densitometry units) in the cardiomyocytes 
from control animals 
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b) Total (T) expression HFD 
No significant differences were observed between the GLUT4 expression in the 
cardiomyocytes from control and HFD animals at baseline; n = 2 biological replicates per 
group analysed in duplicate (Figure 3.61). Furthermore, GLUT4 expression in the 
cardiomyocytes from HFD animals was not influenced in response to the different 
treatments.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.61: GLUT4 expressed as a HFD: Control Ratio 
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CHAPTER 4: DISCUSSION 
 
4. Summary of main findings: 
 The HFD was coupled to the development of insulin resistance, as these animals 
presented with higher: 
 IP fat weight 
 basal glucose  
 insulin levels  
 HOMA IR values  
 downregulated metabolic insulin signalling proteins in the heart. 
 
 The older age-matched control animals were also more resistant to the action of insulin 
when compared to the young control animals.  
 
 KU 60019 inhibited insulin stimulated 2DG uptake in cardiomyocytes from the control and 
HFD animals, placing ATM in the pathway whereby insulin stimulates glucose uptake in 
the heart. 
 
  KU 60019 also significantly attenuated baseline PI3K activation and insulin-stimulated 
activation of ATM and PKB but did not affect AMPK or GLUT4 levels.  
4.1. Body weight & IP fat weight 
An increase in the consumption of food containing high fat, cholesterol, sugar and 
carbohydrate levels are generally associated with an increase in body weight due to the 
imbalance between the amount of energy intake and energy expenditure. Due to such an 
imbalance, insulin resistance can develop when the lipolytic activity of the visceral fat 
cells increases, consequently releasing FFAs in to circulation.  
Before commencing experimentation, we characterized the biometric parameters of the 
model of diet-induced obesity that we aimed to use to ascertain that the animals indeed 
developed obesity and insulin resistance by feeding them a HFD containing high levels of 
fat, cholesterol, sugar and carbohydrates compared to the chow-fed control animals.  
Results indicated that there was no significant difference between the body weight of the 
control and HFD animals; however the HFD animals presented with significantly higher 
IP fat weight gain (Table 3.1; Figure 3.1-3.2). According to Defronzo (2004), obesity and 
Stellenbosch University  https://scholar.sun.ac.za
115 
 
insulin resistance is associated with a larger upper body fat volume (including visceral fat 
and subcutaneous fat) than with a lower body fat volume. 
Visceral fat refers to the fat formation around the organs in the abdomen, whereas 
subcutaneous fat is located directly under the skin (Hirani, 2013). 
Obesity is furthermore also associated with excessive fat storage causing hyperplasia and 
hypertrophy of adipocytes (Goedecke et al, 2006). Hypertrophied adipocytes cause 
activation of several macrophage-attracting chemokines followed by macrophage 
recruitment. The macrophages secrete cytokines (TNF-α and IL-6), causing an 
inflammatory cascade consequently inducing insulin resistance in the mature adipocytes 
(Virtue, 2010). With diet management the number of adipocytes cannot be altered, although 
adipocyte size can decrease (Virtue, 2010). 
If Defronzo’s (2004) observation is taken into consideration, it might be that the HFD 
animals stored most of their fat as abdominal body fat, while the control animals stored 
theirs subcutaneously. As only abdominal fat was evaluated in this study, it might serve as 
a potential reason for the same body weights but different IP fat weights observed in the 
control and HFD animals. Alternatively, the fact that the HFD contained less protein than 
the control diet, may have resulted in a measure of muscle wasting which was not 
assessed in this study. Muscle wasting refers to an imbalance between protein degradation 
and protein synthesis (Livestrong, 2013 – www.livestrong.com). 
 
4.2. Basal glucose levels, Insulin levels & HOMA IR index  
Basal glucose levels, measured after a stable overnight fast, serves as an important 
marker to indicate whether blood glucose levels are regulated normally. Basal blood 
glucose levels in humans according to the American Diabetes Association (ADA) ranges 
between 3.9 mmol/L to 5.5 mmol/L. Glucose, the end product of dietary carbohydrate 
digestion, glycogenolysis (glycogen breakdown in the liver) and gluconeogenesis 
(glucose formation from non-carbohydrate substances) serves as one of the main 
sources of energy for mammalian cells.  
Obesity is associated with an imbalance between energy demand and energy 
expenditure. Consequently, the energy is stored as fat in the adipose tissue, enhancing 
the lipolytic activity of the adipocytes and thereby subsequently causing insulin 
resistance in the liver and muscle tissues (Defronzo, 2004).  
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From the results of this study, the HFD animals had significantly higher basal glucose 
levels (Table 3.1-3.2; Figure 3.3-3.4) when compared to the control animals. The control 
group presented with a basal fasting glucose concentration within the normal range; 
however blood glucose levels of HFD group was only 0.2 mmol/l lower than the insulin 
resistant/prediabetic mark in humans according to Diabetes.co.uk.  Thus it appears that 
the HFD animals were in the process of developing, or were already, insulin resistant. 
Furthermore, after administration of 1g/kg sucrose (Table 3.2; Figure 3.3) the HFD 
animals exhibited lower glucose clearance rates than the control animals within the first 
45 min and at 120 min respectively, indicating that the HFD animals were glucose 
intolerant.  
Due to the high circulating glucose levels associated with obesity, insulin secretion from 
the pancreas increases to compensate for and lower the high glucose levels.  From the 
results obtained, the HFD animals had higher insulin levels when compared to the control 
animals, (Table 3.1; Figure 3.5), compensating partly to lower their glucose levels. 
According to the The New Health Advisor (2015), fasting insulin levels in humans greater 
than 25 mIU/ml are considered as insulin resistant. However, the HFD animals presented 
with 118% elevated insulin levels in comparison to the control animals, indicating a pre-
diabetic state. 
The HOMA IR index was calculated to quantify insulin resistance in the different groups 
(Table 3.1; Figure 3.6). From the results, the HFD animals had a significantly higher 
HOMA IR index value than the control animals, indicating that they were insulin resistant. 
In summary, the HFD did increase the IP fat weight gain but not the total body weight 
measured; indicating that the different animal models may have diverse fat storage 
distributions. The glucose and insulin levels were elevated as expected in obesity, but 
not to such an extent that they match the criteria for diabetes. However, the HOMA IR 
index values and OGTT indicated insulin resistance in the HFD animals.  
 
4.3. Insulin dose response in cardiomyocytes from young control, age-matched 
control and HFD animals 
 
To determine the efficiency and potency of three different insulin concentrations (1 nM, 
10 nM and 100 nM) we used cardiomyocytes from young control, age-matched control 
and HFD animals (Figure 3.7(b)). They were 7-8 weeks and 22 weeks of age 
respectively. Stimulation with INS 10 and INS 100 both enhanced the glucose uptake 
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levels in the cardiomyocytes from control, age-matched control and HFD animals; 
however the response of the age-matched animals were much lower than the younger 
animals, indicating that the age-matched control, older animals, could not respond as 
efficiently to insulin than the younger animals. For the following experiments, we decided 
to use the physiological concentration 10 nM insulin as it will allow any additive effects to 
be detected, whereas the pharmacological concentration of 100 nM insulin would have 
elicited a maximal response that would mask any inhibitory effect such as treatment with 
WM and KU 60019.  
4.4. 2DG uptake and insulin signalling in the control and HFD animals 
Insulin secretion and its action on peripheral, insulin sensitive cells like cardiomyocytes 
are associated with the activation of the PI3K- dependent or the PI3K-independent 
signalling pathways, which consequently results in GLUT4 vesicle translocation for 
increased glucose uptake. From the 2DG uptake results (Figure 3.8) INS 10 stimulation 
increased the 2DG uptake levels in cardiomyocytes from both the control and HFD 
animals, indicating that either the PI3K-dependent or -independent pathway (investigated 
via Western blotting) were activated in both these animal models to increase the amount 
of 2DG uptake by the cells. As expected, treatment with WM and KU 60019 decreased 
the insulin-stimulated 2DG uptake in cardiomyocytes from both the control and HFD 
animals.  
 
WM acts via the covalent attachment of PI3K at the electrophilic C-21 site of WM 
(Norman et al, 1996). Consequently, the activation of all the downstream proteins was 
downregulated, resulting in decreased 2DG uptake. Furthermore, KU 60019 inhibited the 
phosphorylation of the ATM protein (Ying et al, 2014) in cardiomyocytes from both the 
control and HFD animals, resulting in decreased insulin-stimulated 2DG uptake levels via 
an unknown mechanism. From these findings, it was concluded that ATM, in 
cardiomyocytes from both animal models, had an effect on 2DG uptake, and would 
therefore be important in insulin signalling. To gain more insight into ATM’s mode of 
action, Western blotting was performed on cardiomyocytes from control and HFD 
animals as described in the following section (Chapter 4, Section 4.5).  
 
4.5.  Proteins in the insulin signalling pathway 
IRS1: Ser307 phopshorylation of IRS1 was determined in the present study. Ser307 
phosphorylation results in the inhibition of IRS1’s PTB domain function, which is known 
Stellenbosch University  https://scholar.sun.ac.za
118 
 
to disrupt its association with the catalytic domain of the IR (Aguirre et al, 2002). In the 
cardiomyocytes from HFD animals, T-IRS1 expression was significantly upregulated 
while this was in turn downregulated when treated with WM, indicating that the levels of 
IRS1 are regulated in a PI3K-dependent manner (Figure 3.10). A study by Ruiz-Alcaraz 
et al (2005) using muscle biopsies from patients, demonstrated that high insulin levels 
result in a biphasic response on IRS levels, elevating them before the well-known 
downregulation of IRS levels in diabetes.  This effect could be inhibited by the PI3K 
inhibitor, LY294002. Furthermore, there was a twofold increase in the cardiomyocytes 
from HFD animals in IRS1 phosphorylation at Ser307 when compared to the 
cardiomyocytes from control animals at baseline, suggesting that these HFD animals 
were insulin resistant and insulin signalling through the PI3K-dependent pathway was 
therefore most likely disrupted (Figure 3.12). ATM deficient mice have been found to 
have increased JNK levels, which lead to the serine phosphorylation of IRS1 and 
ultimately contributes to the development of insulin resistance (Schneider et al, 2006). 
Furthermore, treatment with WM and KU respectively decreased the phosphorylation of 
IRS1 at Ser307 in cardiomyocytes from the HFD animals. In addition, treatment with WM 
& INS 10 and KU 60019 & INS 10 respectively in the cardiomyocytes from HFD animals 
also resulted in decreased Ser307 phosphorylation when compared to INS 10. Thus the 
inhibition of IRS1 through phosphorylation at Ser307 was no longer restricted in 
response to the two inhibitors. It has previously been shown that the mTOR-p70s6K 
pathway controls serine phosphorylation of IRS1 (Ruiz-Alcaraz et al, 2005).  Results from 
the IRS1 P:T Ratio in the cardiomyocytes from HFD animals (Figure 3.14), indicated that 
WM significantly increased the phosphorylation of IRS1 at Ser307, however this result 
may be misleading, as the T-IRS1 expression after WM treatment was very low. It can 
however, be assumed all of the IRS1 proteins, although low in expression, were 
phosphorylated.  
The IRS1 results might not be completely accurate, as the n-values were very small, due 
to the inability to get any good results with the available antibodies (total and phospho) 
after numerous repetitions. It might be that the specific IRS1 antibodies were not working 
optimally; the IRS1 protein was too big and did not separate or transfer completely on to 
the blot; or that the protein concentration in the cardiomyocytes was too low which makes 
it impossible to visualize on the blot.  
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IRS1 and ATM: Role of ATM was evaluated by the use of the specific ATM inhibitor, KU 
60019, as this KU analogue was tested on 229 kinases and had no or little effect on 
these kinases (Golding et al, 2009). 
As indicated by the use of KU 60019, ATM had no effect on the total expression or 
phosphorylation of IRS1 in cardiomyocytes from the control animals (Figure 3.9; 3.11) 
indicating that ATM is most probably involved in the regulation of downstream insulin 
signalling. In cardiomyocytes from the HFD animals however, further inhibition of the low 
levels of ATM in the presence or absence of INS 10 was able to lower the Ser307 
phosphorylation of IRS1, indicating that ATM activity plays a formerly unrecognized role 
in the inhibition of insulin signalling at the level of IRS1, probably via activation of the 
mTOR-p70s6k signalling pathway (Figure 3.12).     
PI3K: Cardiomyocytes from the HFD animals presented with lower total P85 catalytic 
subunit of PI3K expression when compared to the cardiomyocytes from control animals 
at baseline (Figure 3.16). According to Nadler et al (2001) the downregulation of PI3K is 
associated with insulin resistance, underscoring the results indicating insulin resistance 
in cardiomyocytes from the HFD animals. In cardiomyocytes from the control and HFD 
animals, PI3K phosphorylation was not upregulated in response to INS 10 (Figure 3.17-
3.18). This observation indicates that the PI3K-dependent pathway was not activated in 
cardiomyocytes from both groups to increase the 2DG uptake levels as indicated in 
Figure 3.8. It may be that cardiomyocytes from the age-matched control animals already 
have a measure of insulin resistance at this level as it was also noted that the 2DG 
uptake was significantly lower in cardiomyocytes from these animals than in younger 
control animals (Figure 3.7(b)).    
It may also be that in cardiomyocytes from both animal models, INS 10 stimulation 
resulted in the activation of the PI3K-independent pathway, however no signalling 
proteins in the independent pathway were investigated, so no true assumption can be 
made. Although not significant, we expected cardiomyocytes from the HFD animals to 
have lower PI3K activation levels (Figure 3.18), due to the upregulated Ser307 
phosphorylation which inhibited IRS1 activation (Figure 3.12) and consequently the 
association of PI3K with the pTyr residues of IRS1.  
PI3K and ATM: According to the literature, ATM up to date displayed no direct effects on 
PI3K. Treatment with KU 60019 alone in cardiomyocytes from both the control and HFD 
animals decreased the phosphorylation of PI3K when compared to the respective control 
baseline values (Figure 3.19). In addition, KU 60019 also reduced 2DG uptake in 
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cardiomyocytes from both the control and HFD animals (Figure 3.8). This indicates that 
KU 60019 may have effects on PI3K activity although it is stated in literature that it is 
specific for ATM (Golding et al, 2009). 
PTEN: PTEN is known for its ability to terminate insulin signalling via the hydrolization of 
PIP3 to PIP2, or via the direct de-phosphorylation of IRS1. From the results, no 
differences were observed in the expression or phosphorylation of PTEN in response to 
the different treatments in cardiomyocytes from both the control and HFD animals (Figure 
3.22-3.27), therefore PTEN activity were not changed. 
PTEN and ATM: The inhibition of ATM did not alter PTEN expression or phosphorylation 
(Figure 3.22-27, therefore any changes in the insulin signalling pathway in response to 
ATM cannot be attributed to changes in PTEN activity. 
ATM: As described in Chapter1, Section 6.5, ATM according to several studies plays an 
important role in the regulation of insulin signalling. From what is known, ATM in 
response to insulin stimulation, can activate 4EBP1 (Yang & Kastan, 2000), PKB via PP1 
or PP4-6 (Viniegra et al, 2005; Halaby et. al, 2008) or AMPK via LKB phosphorylation 
(Shackelford & Shaw, 2009).  
From the results of the current study, cardiomyocytes from the HFD animals, as 
expected, presented with lower T-ATM expression levels when compared to 
cardiomyocytes from the control animals at baseline, which therefore correlate with the 
observation of Schneider et al (2006) that downregulated ATM is associated with insulin 
resistance (Figure 3.29). Interestingly, cardiomyocytes from both groups treated with KU 
60019 & INS 10 had decreased T-ATM expression levels when compared to the 
respective INS 10 groups (Figure 3.28-3.29), which suggests that ATM expression is 
regulated through the insulin signalling pathway. This may be because ATM regulates 
the activation of both eIF-4E and p70s6k activity, thereby regulating protein synthesis 
(Bevan, 2009). Consequently these effects are inhibited by KU 60019, resulting in lower 
expression of the protein.    
KU 60019 treatment in cardiomyocytes from the control and HFD animals significantly 
decreased the insulin-stimulated phosphorylation of ATM in the cytosol when compared 
to INS 10 (Figure 3.31-3.32). It is possible that the effect of KU 60019 under basal 
conditions was more outspoken in cardiomyocytes from the HFD animals with their lower 
baseline expression and phosphorylation levels of ATM. 
Stellenbosch University  https://scholar.sun.ac.za
121 
 
The ATM P:T Ratio of cardiomyocytes from the control animals indicated that KU 60019 
increased the phosphorylation levels of ATM when compared to baseline values (Figure 
3.33). However, KU 60019 also downregulated the expression levels of ATM. It is 
therefore not possible to extrapolate the active kinase from this result (Figure 3.28).  
The ATM P:T Ratio of cardiomyocytes from the HFD animals showed that INS 10 
treatment decreased the phosphorylation of ATM when compared to baseline values 
(Figure 3.34), thus exacerbating the effects of the lower T-ATM expressed in these HFD 
animals (Figure 3.29). It must also be kept in mind that these animals are insulin 
resistant, therefore present with low insulin-stimulated activity. Furthermore, the P:T 
Ratio confirmed that treatment with KU 60019 in cardiomyocytes from the HFD animals 
significantly inhibited the phosphorylation of ATM when compared to the HFD baseline 
group (Figure 3.34).  
From the above it is evident that ATM in cardiomyocytes of the HFD animals was not 
activated in response to INS 10 stimulation as expected. This may again be attributed to 
cardiomyocytes from the age-matched, older animals who already display aspects of 
insulin resistance, as observed in the 2DG uptake results (Figure 3.7(b)). 
PKB: In cardiomyocytes from the HFD animals, T-PKB expression was 40% lower when 
compared to the control animals at baseline (Figure 3.36). As shown in Figure 3.49 and 
Figure 3.51, we also found that GSK3 expression and activity was lower in 
cardiomyocytes from the HFD animals.  It has been demonstrated previously that 
inhibition of GSK-3 leads to downregulation of PKB expression through the beta-catenin 
pathway.  This pathway, which is normally inhibited by GSK-3, regulates PKB 
expression (Wade, 2009). 
Stimulation with INS 10 in cardiomyocytes from the control and HFD animals resulted in 
no detectable activation of PKB (Figure 3.37-3.38). We would have expected this 
observation in cardiomyocytes from the HFD animals, as they were insulin resistant and 
signalling through IRS1 was disrupted. This again, is a clear indication that 
cardiomyocytes from the age-matched, older animals were also becoming insulin 
resistant.  
PKB and ATM: According to Viniegra et al (2005) and Halaby et al (2008) ATM 
phosphorylates PKB which results in increased glucose uptake by the cell. In these 
experiments, the effect of KU 60019 on insulin-stimulated cardiomyocytes from both the 
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control and HFD animals was significant (Figure 3.39). Thus our results correlated with 
literature that ATM might be a potential activator of PKB in the context of glucose uptake. 
AS160: AS160 is activated in response to the insulin mediated activation of PKB (Klip et 
al, 2014) or, according to new evidence via the ATM/LKB/AMPK pathway (Shackelford & 
Shaw, 2009). When AS160 is activated, it initiates GLUT4 vesicle translocation via the 
conversion of Rab-GDP to Rab-GTP, consequently increasing glucose uptake by the 
cell.  
From the results (Figure 3.42-3.43), the T-AS160 expression levels of cardiomyocytes 
from the control and HFD animals showed no significant differences in response to the 
different treatments. In cardiomyocytes from the control animals, treatment with WM 
significantly decreased the phosphorylation of AS160 when compared to the baseline 
control animals (Figure 3.43; 3.46). One would expect WM to decrease the activation of 
AS160 as it inhibits the PI3K pathway; however no direct inhibition of phosphorylation in 
response to WM was seen in the PI3K results.  
As observed in a previous study conducted by Middelbeek et al (2013), cardiomyocytes 
from the HFD animals presented with impaired AS160 phosphorylation at Thr642 when 
compared to cardiomyocytes from the control animals at baseline (Figure 3.45). 
Stimulation with INS 10 however still increased the phosphorylation of AS160 in 
cardiomyocytes from the HFD animals when compared to baseline values (Figure 3.45; 
3.47), although it could not have been via the PKB pathway, as PKB was not activated in 
cardiomyocytes from both the control and HFD animals. Therefore, the activation of 
AS160 in cardiomyocytes from the HFD animals in response to INS 10 was either via 
ATM/LKB/AMPK or directly from the IR through an unknown mechanism.   
AS160 and ATM: Inhibition of ATM had no significant effect on the phosphorylation of 
AS160 in cardiomyocytes from both animal groups either in the presence or absence of 
INS 10 stimulation. This therefore still leaves the inhibition of 2DG uptake by KU 60019 
unresolved. 
GSK-3β: The phosphorylation of GSK-3β at Ser9 via PKB results in the inactivation of 
this protein, consequently activating GS for glycogen synthesis.  
From the results, once again, cardiomyocytes from the HFD animals presented with 
significantly less T-GSK-3β and P-GSK-3β levels when compared to cardiomyocytes 
from the control animals, indicating the HFD induced insulin resistance in these animals 
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(Figure 3.49; 3.51). As argued above, GSK-3β probably regulated the expression of PKB 
as observed in cardiomyocytes from the HFD animals. According to the GSK-3β P:T 
Ratio in cardiomyocytes from the HFD animals, INS 10 was able to significantly 
upregulate the phosphorylation of GSK-3β, indicating that INS 10 was still able to 
phosphorylate the low T-GSK-3β levels expressed in these HFD animals (Figure 3.53).  
GSK-3β and ATM: In cardiomyocytes from the control animals, the inhibition of ATM 
resulted in a significantly higher T-GSK-3β expression level, indicating that active ATM 
supresses the T-GSK-3β levels and less glycogen synthesis can occur via this pathway 
(Figure 3.48). ATM had no effect on the activation of GSK-3β in cardiomyocytes from 
both the control or HFD animals (Figure 3.50-3.53). 
AMPK: According to Shackelford & Shaw (2009) AMPK is activated in response to 
insulin via ATM; however the exact mechanism is not yet fully understood. From the 
results, WM stimulated T-AMPK expression in cardiomyocytes from the control animals, 
but not in cardiomyocytes from the HFD animals when compared to the respective 
baseline values (Figure 3.54), which indicates that AMPK expression is regulated 
negatively by the insulin-PI3K pathway. The drivers that regulate AMPK expression have 
not been defined (Zaha & Young, 2012) but both the actions of MiRNA’s as well 
degradation through the proteasomal pathway, are mentioned as possible regulatory 
mechanisms. 
AMPK in cardiomyocytes from both the control and HFD animals were not activated at all 
via INS 10 stimulation when compared to the respective baseline values (Figure 3.56-
3.57) which correlates with the ATM Western blot results where ATM also wasn’t 
activated in response to INS 10 stimulation (Figure 3.30-3.31). 
Cardiomyocytes from the HFD once again resulted in downregulation of T-AMPK and P-
AMPK levels (Figure 3.55; 3.57) when these cardiomyocytes were compared to the 
cardiomyocytes from the control animals at baseline. This downregulation may have an 
effect on the PI3K-independent pathway for glucose uptake via GLUT4 as AMPK is 
believed to regulate GLUT4 expression (Ojuka et al, 2000). 
AMPK and ATM: ATM did not have any effect of the regulation of AMPK levels in 
cardiomyocytes from the control or the HFD animals (Figure 3.54-3.59). 
GLUT4: The initiation of GLUT4 vesicle translocation to the plasma membrane is 
important for glucose uptake by the cell. GLUT4 is translocated via the PI3K-dependent 
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pathway or via the ATM/LKB/AMPK pathway. From the results, stimulation with INS 10 
significantly increased the total expression of GLUT4 in cardiomyocytes from the control 
animals when compared to baseline values, indicating that GLUT4 protein levels may be 
controlled by insulin levels in the cell (Figure 3.60). WM surprisingly also increased the 
expression of GLUT4 in cardiomyocytes from the control animals when compared to 
baseline values, which correlates with the increase in T-AMPK in response to WM 
(Figure 3.54), indicating that a different pathway than the PI3K-dependent pathway may 
be responsible for the increase in GLUT4 expression.  This underscores the observation 
by Ojuka et al (2000) that 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR), an 
activator of AMPK, which is converted to the adenosine monophosphate (AMP) analog, 
AICAR monophosphate (ZMP) once it enters the cell, can result in the upregulation of 
GLUT4 expression in skeletal muscle.   
In cardiomyocytes from the HFD animals, we expected the GLUT4 expression to be 
downregulated when compared to the control animals, as the HFD animals presented 
with lower AMPK expression (Figure 3.55) and a 30% downregulated phosphorylation of 
AS160 (Figure 3.45). From the results, there were no differences observed in GLUT4 
expression in cardiomyocytes from these HFD animals (Figure 3.61). These results might 
not be completely accurate, as the n-value was very small, due to the inability to get any 
results after numerous repetitions of the Western blots, but it has been demonstrated in 
skeletal muscle, that GLUT4 expression is mostly downregulated in conditions of severe 
insulin deficiency but not consistently in diabetes (Zaha & Young, 2012).   In addition, it is 
argued in literature that the low insulin-responsive glucose uptake in skeletal muscle is 
not because of low GLUT4 expression but because of defective translocation of the 
protein, an aspect that has not been measured in the current study. 
 
GLUT4 and ATM: Inhibition of ATM had no direct effect on GLUT4 expression in 
cardiomyocytes from both the control and HFD animals, correlating with the lack of effect 
seen on AMPK.  
 
4.6. General discussion and conclusion  
The HFD was coupled to whole-body insulin resistance as the HFD animals were less 
responsive to insulin within the first 60 min, and on 120 min (Figure 3.3) of the OGTT 
when compared to the control animals. In addition they also presented with significantly 
higher basal glucose (Figure 3.4), insulin (Figure 3.5) and HOMA IR (Figure 3.6) levels 
when compared to the control animals.  From the Western blot results, cardiomyocytes 
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from the HFD animals had downregulated T-PI3K, T-ATM, T-PKB, T-GSK3β and T-
AMPK expression as well as downregulated phosphorylation of ATM, AS160, GSK3β, 
AMPK and increased phosphorylation of IRS1 at Ser307. These observations also, 
therefore demonstrate that the cardiomyocytes from the HFD animals presented with a 
profile of insulin resistance.   
The 2DG uptake results (Figure 3.8) showed that stimulation with INS 10 in both the 
control and HFD animals increased the amount of glucose uptake in the cardiomyocytes 
to the same extent. Importantly, especially for the current study was to determine 
whether ATM plays a direct role in the regulation of glucose uptake by the cells and the 
development of insulin resistance.  
2DG uptake results in both animal models indicated that the inhibition of ATM via KU 
60019 decreased the amount of 2DG uptake in insulin-stimulated cardiomyocytes. We 
can therefore conclude that the activity of ATM is necessary for insulin-stimulated 
glucose uptake. Due to this observation, we investigated signalling events controlling 
2DG uptake, using Western blotting techniques to determine how ATM is involved in the 
regulation of glucose uptake. Inhibition of ATM also lowered the Ser307 phosphorylation 
of IRS1 in cardiomyocytes from the HFD animals (Figure 3.12), indicating a possible 
improvement in insulin signalling.  
Western blot data demonstrated that stimulation with INS 10 in cardiomyocytes from both 
animal models did not activate ATM as measured by phosphorylation of Ser1981 (Figure 
3.30-3.31). ATM therefore must have been activated via a different mechanism to initiate 
glucose uptake as seen in the 2DG uptake results. According to studies done by Guo et 
al (2010) and Pellegrini et al (2006), ATM is not only active once phosphorylated at 
Ser1981. As ATM is believed to have three additional autophosphorylation sites 
including: Ser367, Ser1893, and Ser2996 (Kozlov et al, 2011) and we only investigated 
phosphorylation of ATM at the Ser1981 site, it might be that ATM was phosphorylated at 
a different phosphorylation site resulting in activation. This however needs to be 
investigated in future studies.  
Furthermore, inhibition of ATM, regulated the phosphorylation of the P85 subunit of PI3K 
in cardiomyocytes from both animal models (Figure 3.19), indicating that the inhibitor 
may not be as specific as reported in literature (Golding et al, 2009).  This observation 
makes it very difficult to distinguish between ATM effects and PI3K-mediated effects. As 
activation of PI3K is a prerequisite for insulin-stimulated glucose uptake, this sheds some 
doubt on the above conclusion that ATM activity is necessary for insulin-stimulated 
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glucose uptake. It will only be possible to determine this association accurately by either 
silencing ATM in cardiomyocytes or using a commercially available ATM-KO cell line as 
surrogate.     
According to a study done by Andrisse et al (2013), ATM can directly phosphorylate 
GLUT1 in the skeletal muscle at a specific Ser490 site. GLUT1, located predominately in 
the plasma membrane of the skeletal muscle, has a COOH-terminus containing a PDZ 
binding motif on which the specific ATM Ser490 phosphorylation site is located. Once 
phosphorylated, it interacts with the Gα-interacting protein C terminus 1 (GIPC1) 
(Matsuoka et al, 2007). This interaction between GLUT1 and GIPC1 is believed to 
increase GLUT1’s externalization to the plasma membrane for GLUT1-mediated glucose 
transport (Andrisse et al, 2013). Whether this mechanism was active in our study is not 
known, as we did not investigate the relationship between ATM and GLUT1 in the current 
study. Therefore more studies are needed to elucidate the specific relationship between 
ATM and GLUT1 in cardiomyocytes. 
More-over, ATM is associated with vesicular structures and can bind to the membrane 
proteins Vesicle-associated membrane protein 2 (VAMP2) and synapsin, two major 
components of synaptic vesicles (Li et al, 2009). Both these proteins are also 
components of the glucose transporter GLUT4-containing vesicles in muscle cells and 
therefore are involved in insulin-mediated GLUT4 translocation to the plasma membrane 
(Dugani & Klip, 2005). In L6 myoblasts, inhibition of ATM abolished the insulin-regulated 
GLUT4 translocation process (Halaby et al, 2008). 
It is therefore possible that the primary effect of KU 60019 to inhibit glucose uptake, does 
not lie in any of the signalling intermediates that was determined in this study, but that it 
inhibits the insertion of the GLUT4 protein into the plasma membrane.   
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4.7. Summarized effect of HFD (indicated in red) and ATM (KU 60019) (indicated in 
green) on the insulin signalling proteins  
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Summarized effect of HFD and ATM (KU 60019) on the insulin signalling 
proteins  
Conclusion: The HFD was coupled to the development of insulin resistance, as these 
animals presented with higher IP fat weight, basal glucose and insulin levels as well as 
downregulation of multiple metabolic insulin signalling proteins and insulin sensitivity in 
the heart. The older age-matched control animals were also more resistant to the action 
of insulin when compared to the young control animals. KU 60019 inhibited insulin 
stimulated 2DG uptake in cardiomyocytes from the control and HFD animals, placing 
ATM in the pathway whereby insulin stimulates glucose uptake in the heart. KU 60019 
also significantly attenuated baseline PI3K activation and insulin-stimulated activation of 
ATM and PKB but did not affect AMPK or GLUT4 levels. We conclude that the 
downregulation of expression of ATM in insulin resistant states may be central to the 
development of myocardial insulin resistance.  
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CHAPTER 5: LIMITATIONS AND FUTURE RESEARCH 
 The age-matched control animals were less responsive to insulin when compared to 
young control animals, indicating possible insulin resistance in this model. 
 The effect of Metformin on ATM activation should be investigated. 
 The n-value of IRS1 in both the age-matched control and HFD animals should be 
enlarged for consistency in the results. 
 GLUT4 expression as well as the translocation of GLUT4 vesicles should be investigated 
in the age-matched control and HFD animals. 
 The effect of ATM on GLUT1 should be investigated to determine the possible 
relationship of ATM and GLUT1 for glucose uptake. 
 The phosphorylation of ATM at Ser367, Ser1893, and Ser2996 should be studied to 
determine whether ATM was activated at a different site.  
 In view of the possibility that KU 60019 is not specific for ATM, as PI3K was inhibited in 
response to KU 60019 treatment, silencing of the ATM protein in cardiomyocytes should 
be attempted or a commercially available KO cell line used to determine specific actions. 
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